Treatment of psoriasis with interferon-induced helicase C domain 1 (IFIH1) inhibitors

Abstract

The present disclosure provides methods of treating a subject with psoriasis, and methods of identifying a subject at high risk of developing psoriasis.

Description

[Technical field]

[0001] Sequence Listing Reference This application contains a Sequence Listing that has been submitted electronically as a text file of 228 kilobytes in size under the title 18923800302SEQ, created on June 9, 2022. The Sequence Listing is incorporated herein by reference.

[0002] The present disclosure relates generally to the treatment of subjects with psoriasis with an interferon-induced helicase C domain 1 (IFIH1) inhibitor and / or a Tripartite Motif Containing 65 (TRIM65) inhibitor, as well as methods of identifying subjects at high risk of developing psoriasis. [Background technology]

[0003] Psoriasis is an autoimmune skin disease characterized by the presence of small bumps on the skin in addition to silvery white scales. These psoriatic lesions most often occur on the elbows, knees, trunk and scalp. In the areas where the scales fall off, tiny bleeding points appear, called the "Auspitz phenomenon". The main pathophysiological events involved in the course of the disease are increased epidermal proliferation and metabolic activity, proliferation of capillaries in the dermal area, and infiltration of the dermis and epidermis by inflammatory cells. Coal tar and salicylic acid are the only two category I drugs mentioned in the final monograph on drugs for dandruff, seborrheic dermatitis and psoriasis. There are also several prescription drugs that are similarly useful, such as theophylline, that block cell proliferation during metaphase of cell division.

[0004] Psoriasis is believed to be a genetic disease caused by environmental factors. For example, symptoms are often worse in the winter and with certain medications, such as beta-blockers or NSAIDs. Infection and psychological stress can also be triggers. These periods of disease exacerbation are called acute exacerbations. There are five main types of psoriasis: plaque, guttate, inverse, pustular, and erythrodermic. Plaque psoriasis, also known as plaque psoriasis, is the most common, accounting for about 90 percent of cases. It typically presents as red patches with white scales on top. The most commonly affected areas of the body with psoriasis are the back, shins, central areas, and scalp. Guttate psoriasis has droplet-shaped lesions. Pustular psoriasis presents with small, non-infectious pustules. Erythrodermic psoriasis occurs when the rash is very widespread and can arise from any of the other types. In most patients, changes in the color of the fingernails and toenails often occur.

[0005] The pathogenesis of psoriasis involves the immune system responding to skin cells. Skin cells are replaced every 3-5 days in psoriasis instead of the usual 28-30 days. These changes are thought to result from premature maturation of keratinocytes triggered by an inflammatory cascade in the dermis involving dendritic cells, macrophages, and T cells. These immune cells migrate from the dermis to the epidermis and secrete inflammatory chemical signals (cytokines), such as interleukins, tumor necrosis factor-a, interleukin-1b, interleukin-6, and interleukin-22. These secreted inflammatory signals are thought to stimulate keratinocytes to proliferate.

[0006] Interferon-induced helicase C domain 1 (IFIH1) encodes an innate immune receptor that acts as a cytoplasmic sensor of viral nucleic acids and plays a key role in detecting viral infection and activating a cascade of antiviral responses, including induction of type I interferons and inflammatory cytokines. Its ligands include mRNAs lacking 2'-O-methylation at the 5' cap and long dsRNAs (length >1 kb). Upon ligand binding, IFIH1 associates with mitochondrial antiviral signaling protein (MAVS / IPS1), which activates the IKK-related kinases TBK1 and IKBKE, which phosphorylate the interferon regulatory factors IRF3 and IRF7, which in turn activate the transcription of antiviral immune genes, including interferons (IFNs), IFN-alpha, and IFN-beta. IFIH1 plays a role in detecting Picornaviridae family members, such as encephalomyocarditis virus (EMCV) and Mengo encephalomyocarditis virus (ENMG). IFIH1 also plays an important role in amplifying innate immune signaling through the recognition of RNA metabolites produced by ribonuclease L (RNase L) during viral infection. IFIH1 may be involved in enhancing natural killer cell function and may be involved in the growth suppression and apoptosis of some tumor cell lines.

[0007] Tripartite Motif Containing 65 (TRIM65) is an E3 ubiquitin ligase and regulator of various cellular processes and tumor progression. By sequence consensus, TRIM65 belongs to the tripartite motif family. TRIM65 was initially identified as a gene with a SNP associated with cerebral white matter lesions, but was subsequently found to be a cofactor for the regulation of microRNA function. TRIM65 regulates microRNA activity by ubiquitinating TNRC6, establishing its E3 ubiquitin ligase activity. Like other TRIM members involved in immune responses, TRIM65 also participates in virus-induced innate immune responses by ubiquitinating substrate proteins. Summary of the Invention

[0008] The present disclosure provides a method of treating a subject with psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0009] The disclosure also provides a method of treating a subject with guttate psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0010] The disclosure also provides a method of treating a subject having plaque psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0011] The disclosure also provides a method of treating a subject with inverse psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0012] The disclosure also provides a method of treating a subject having pustular psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0013] The present disclosure also provides a method of treating a subject having erythrodermic psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0014] The disclosure also provides a method of treating a subject with a therapeutic agent that treats or inhibits psoriasis, the subject having psoriasis, the method comprising determining whether the subject has an IFIH1 missense variant nucleic acid molecule by obtaining or obtaining a biological sample from the subject and performing or having performed a sequence analysis in the biological sample to determine whether the subject has a genotype that includes an IFIH1 missense variant nucleic acid molecule that encodes a predicted loss-of-function polypeptide of IFIH1, and administering or continuing to administer the therapeutic agent that treats or inhibits psoriasis at a standard dosage to a subject that is an IFIH1 reference, and / or administering an IFIH1 inhibitor to the subject, administering or continuing to administer a therapeutic agent for treating or suppressing psoriasis to a subject who is heterozygous for the IFIH1 missense variant nucleic acid molecule at or below a standard dosage, and / or administering an IFIH1 inhibitor to the subject; or administering or continuing to administer a therapeutic agent for treating or suppressing psoriasis to a subject who is homozygous for the IFIH1 missense variant nucleic acid molecule at or below a standard dosage, wherein the presence of a genotype having an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 indicates that the subject is at low risk of developing psoriasis.

[0015] The present disclosure also provides a method for identifying a subject at high risk of developing psoriasis, the method comprising determining the presence or absence, or having determined, in a biological sample obtained from a subject, of an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1, where if the subject is IFIH1 reference, the subject is at high risk of developing psoriasis, and if the subject is heterozygous or homozygous for an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1, the subject is at low risk of developing psoriasis.

[0016] The present disclosure also provides a therapeutic agent for treating or inhibiting psoriasis for use in treating psoriasis in a subject having a genomic nucleic acid molecule having a nucleotide sequence encoding an IFIH1 polypeptide, the nucleotide sequence comprising a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2, or a complement thereof.

[0017] The present disclosure also provides an IFIH1 inhibitor for use in treating psoriasis in a subject who is an IFIH1 reference or who is heterozygous for an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1.

[0018] The disclosure also provides a method of treating a subject with psoriasis, the method comprising administering a TRIM65 inhibitor to the subject.

[0019] The disclosure also provides a method of treating a subject with a therapeutic agent that treats or inhibits psoriasis, the subject having psoriasis, the method comprising determining whether the subject has a TRIM65 missense variant nucleic acid molecule by obtaining or obtaining a biological sample from the subject and performing or having performed a sequence analysis in the biological sample to determine whether the subject has a genotype that includes a TRIM65 missense variant nucleic acid molecule that encodes a predicted loss-of-function polypeptide of TRIM65, and administering or continuing to administer the therapeutic agent that treats or inhibits psoriasis at a standard dosage to a TRIM65 reference subject and / or administering a TRIM65 inhibitor to the subject, The method includes administering or continuing to administer a therapeutic agent for treating or suppressing psoriasis to a subject who is heterozygous for the TRIM65 missense variant nucleic acid molecule, at the same or lower than a standard dosage, and / or administering a TRIM65 inhibitor to the subject, or administering or continuing to administer a therapeutic agent for treating or suppressing psoriasis to a subject who is homozygous for the TRIM65 missense variant nucleic acid molecule, at the same or lower than a standard dosage, wherein the presence of a genotype having a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 indicates that the subject is at low risk of developing psoriasis.

[0020] The present disclosure also provides a method for identifying a subject at high risk of developing psoriasis, the method comprising determining or having determined the presence or absence of a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 in a biological sample obtained from the subject, where if the subject is a TRIM65 reference, the subject has a high risk of developing psoriasis, and if the subject is heterozygous or homozygous for a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65, the subject has a low risk of developing psoriasis.

[0021] The present disclosure also provides therapeutic agents that treat or inhibit psoriasis for use in treating psoriasis in a subject having a TRIM65 missense variant nucleic acid molecule that encodes a predicted loss-of-function polypeptide of TRIM65.

[0022] The present disclosure also provides TRIM65 inhibitors for use in treating psoriasis in a subject who is a TRIM65 reference or who is heterozygous for a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65.

[0023] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several features of the present disclosure.

[0024] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Brief description of the drawings]

[0025] [Figure 1] We show that a common TRIM65 psoriasis variant is an eQTL for increased TRIM65 expression in the skin. [Figure 2-1]Immunofluorescence analysis of HEK293-HZ cells transiently transfected with N-HA-IFIH1 and N-FlagTRIM65-WT (top) or N-FlagTRIM65-G382R (bottom), revealing aberrant expression of TRIM65-G382R protein (panel A), % colocalization of N-HA-IFIH1 with WT and TRIM65-G382R (panel B), % colocalization of WT TRIM65 and TRIM65-G382R with IFIH1 (panel C), Manders correlation between N-HA-IFIH1 and N-FlagTRIM65-WT or N-FlagTRIM65-G382R. Overlap coefficients (ranging from 0.0 for no colocalization to 1.0 for complete colocalization) reveal significantly lower colocalization between IFIH1 and TRIM65-G382R (panel D), Western blot analysis reveals reduced expression in N-Flag-TRIM65-G382R compared to N-Flag-TRIM65-WT (panel E), as well as expression in cells transfected with empty vector, N-eGFP-TRIM65-WT, or N-eGFP-TRIM65-G382R. Shown are transfected HEK-ISRE-Luc reporter cells (panels F and G); ISRE activation was measured by luciferase reporter activity in response to 0.05 μg poly(i:c) (panel F) and 5000 U of IFN-α (panel G) in 96-well plates; cells transfected with N-eGFP-TRIM65-G382R showed lower ISRE activation in response to poly(i:c) and IFN-α compared to N-eGFP-TRIM65-WT. [Figure 2-2] Same as above. [Figure 2-3] Same as above. [Figure 2-4] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] Various terms relating to aspects of the present disclosure are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art unless otherwise indicated. Other specifically defined terms are to be interpreted in a manner consistent with the definitions provided herein.

[0027] Unless expressly stated otherwise, it is in no way intended that any method or aspect described herein be construed as requiring that its steps be performed in a particular order. Thus, unless a method claim specifically states in the claim or description that the steps are to be limited to a particular order, no order is intended to be implied in any respect. This also applies to any possible unstated criteria for interpretation, including questions of logic regarding the arrangement of steps or operational flow, the plain meaning derived from grammatical construction or punctuation, or the number or type of aspects described herein.

[0028] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0029] As used herein, the term "about" means that the recited numerical values ​​are approximate and that small variations do not significantly affect the practice of the disclosed embodiments. When numerical values ​​are used, unless otherwise indicated by the context, the term "about" means that the numerical values ​​can vary by ±10% and remain within the scope of the disclosed embodiments.

[0030] As used herein, the term "comprising" may in certain embodiments be replaced with "consisting of" or "consisting essentially of," as desired.

[0031] As used herein, the term "isolated" in reference to a nucleic acid molecule or polypeptide means that the nucleic acid molecule or polypeptide is in a state other than its native environment, e.g., away from blood and / or animal tissue. In some embodiments, an isolated nucleic acid molecule or polypeptide is substantially free of other nucleic acid molecules or other polypeptides, particularly other nucleic acid molecules or polypeptides of animal origin. In some embodiments, the nucleic acid molecule or polypeptide may be in a highly purified form, i.e., more than 95% pure or more than 99% pure. When used in this context, the term "isolated" does not exclude the presence of alternative physical forms, e.g., dimers of the same nucleic acid molecule or polypeptide, or alternative phosphorylated or derivatized forms.

[0032] As used herein, the terms "nucleic acid," "nucleic acid molecule," "nucleic acid sequence," "polynucleotide," or "oligonucleotide" can include polymeric forms of nucleotides of any length, can include DNA and / or RNA, and can be single-stranded, double-stranded, or multistranded. A strand of a nucleic acid also refers to its complement.

[0033] As used herein, the term "subject" includes any animal, including mammals. Mammals include, but are not limited to, farm animals (e.g., horses, cows, pigs, etc.), pet animals (e.g., dogs, cats, etc.), laboratory animals (e.g., mice, rats, rabbits, etc.), and non-human primates. In some embodiments, the subject is a human. In some embodiments, the human is a patient of a physician.

[0034] The present disclosure identifies rare variants of IFIH1 gene that are associated with reduced risk of developing psoriasis in humans.For example, it has been observed that a genetic change that changes the guanine at position 38,690 in human IFIH1 reference (see SEQ ID NO: 1) to cytosine indicates that people with such a change may have reduced risk of developing psoriasis.Overall, the genetic analysis described herein surprisingly shows that IFIH1 gene and, in particular, variants of IFIH1 gene are associated with reduced risk of developing psoriasis.Therefore, subjects with IFIH1 reference that are at high risk of developing psoriasis can be treated to prevent psoriasis, alleviate its symptoms, and / or inhibit the onset of symptoms. Thus, the present disclosure provides methods utilizing the identification of such variants in a subject to identify or stratify the risk of developing psoriasis in such a subject, e.g., plaque psoriasis, guttate infection, inverse infection, pustular psoriasis and / or erythrodermic psoriasis, or diagnose a subject as being at high risk of developing psoriasis, e.g., plaque psoriasis, guttate infection, inverse infection, pustular psoriasis and / or erythrodermic psoriasis, so that subjects at risk or with active disease may be treated accordingly.

[0035] The TRIM65 Gly382Arg variant was observed to alter the cellular localization and expression levels of TRIM65. TRIM65 Gly382Arg shows reduced colocalization with its binding partner, IFIH1. This observation, together with the reduced interferon-stimulated response element (ISRE) activity in response to stimulation with IFN-a or poly(i:c) in cells transfected with the TRIM65 Gly382Arg construct, suggests that this variant may result in reduced interferon pathway activation, which may be protective against psoriasis.

[0036] According to the present disclosure, it is further observed that the total burden of mutations in IFIH1 is associated with a reduced risk of developing psoriasis. According to the present disclosure, it is also observed that the total burden of IFIH1 missense variant nucleic acid molecules encoding predicted loss-of-function polypeptides of IFIH1 has a cumulative protective effect in reducing the risk of developing psoriasis, such as plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis and / or erythrodermic psoriasis. Therefore, it is believed that people with psoriasis can be treated with molecules that inhibit IFIH1. Thus, the present disclosure provides a method for identifying or stratifying the risk of psoriasis in a subject, or diagnosing a subject as having psoriasis, and treating subjects at risk or with active disease, by utilizing the identification of such variants in a subject and the total burden of having such variants.

[0037] For the purpose of this disclosure, any particular subject can be classified as having one of three IFIH1 genotypes: i) IFIH1 reference, ii) heterozygous for IFIH1 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of IFIH1, or iii) homozygous for IFIH1 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of IFIH1.If a subject does not have a copy of IFIH1 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of IFIH1, the subject is IFIH1 reference.If a subject has a single copy of IFIH1 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of IFIH1, the subject is heterozygous for IFIH1 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of IFIH1. The IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 is any IFIH1 nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) encoding an IFIH1 polypeptide with partial loss-of-function, complete loss-of-function, predicted partial loss-of-function, or predicted complete loss-of-function. A subject having an IFIH1 polypeptide with partial loss-of-function (or predicted partial loss-of-function) is hypomorphic with respect to IFIH1. In some embodiments, the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 is an IFIH1 genomic nucleic acid molecule that contains a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2. If a subject has two copies of the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1, the subject is homozygous for the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1.

[0038] For subjects genotyped or identified as IFIH1 reference, such subjects are at increased risk of developing psoriasis, e.g., plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, and / or erythrodermic psoriasis. For subjects genotyped or identified as heterozygous for an IFIH1 reference or an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1, such subjects may be treated with an IFIH1 inhibitor.

[0039] In any of the embodiments described herein, the IFIH1 missense variant nucleic acid molecule encoding the predicted loss-of-function polypeptide of IFIH1 can be any IFIH1 nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) encoding an IFIH1 polypeptide with partial loss-of-function, complete loss-of-function, predicted partial loss-of-function, or predicted complete loss-of-function.For example, the IFIH1 missense variant nucleic acid molecule encoding the predicted loss-of-function polypeptide of IFIH1 comprises a cytosine at the position corresponding to position 38,690 according to SEQ ID NO:2.

[0040] In any of the embodiments described herein, the predicted loss-of-function polypeptide of IFIH1 can be any IFIH1 polypeptide having a partial loss-of-function, a complete loss-of-function, a predicted partial loss-of-function, or a predicted complete loss-of-function. In any of the embodiments described herein, the predicted loss-of-function polypeptide of IFIH1 can be any of the IFIH1 polypeptides described herein.

[0041] For the purpose of this disclosure, any particular subject can be classified as having one of three TRIM65 genotypes: i) TRIM65 reference, ii) heterozygous for TRIM65 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of TRIM65, or iii) homozygous for TRIM65 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of TRIM65.If a subject does not have a copy of TRIM65 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of TRIM65, the subject is TRIM65 reference.If a subject has a single copy of TRIM65 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of TRIM65, the subject is heterozygous for TRIM65 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of TRIM65. The TRIM65 missense variant nucleic acid molecule encoding the predicted loss-of-function polypeptide of TRIM65 is any TRIM65 nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) encoding a TRIM65 polypeptide with partial loss-of-function, complete loss-of-function, predicted partial loss-of-function, or predicted complete loss-of-function. The subject having a TRIM65 polypeptide with partial loss-of-function (or predicted partial loss-of-function) is hypomorphic for TRIM65. In some embodiments, the predicted loss-of-function polypeptide of TRIM65 is TRIM65 Gly382Arg. If a subject has two copies of the TRIM65 missense variant nucleic acid molecule encoding the predicted loss-of-function polypeptide of TRIM65, the subject is homozygous for the TRIM65 missense variant nucleic acid molecule encoding the predicted loss-of-function polypeptide of TRIM65.

[0042] For subjects genotyped or identified as TRIM65 reference, such subjects are at increased risk of developing psoriasis, e.g., plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, and / or erythrodermic psoriasis. For subjects genotyped or identified as heterozygous for a TRIM65 reference or a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65, such subjects may be treated with a TRIM65 inhibitor.

[0043] In any of the embodiments described herein, the TRIM65 missense variant nucleic acid molecule encoding the predicted loss-of-function polypeptide of TRIM65 can be any TRIM65 nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) that encodes a TRIM65 polypeptide with partial loss-of-function, complete loss-of-function, predicted partial loss-of-function, or predicted complete loss-of-function.For example, the TRIM65 missense variant nucleic acid molecule encoding the predicted loss-of-function polypeptide of TRIM65 can encode TRIM65 Gly382Arg.

[0044] In any of the embodiments described herein, the predicted loss-of-function polypeptide of TRIM65 may be any TRIM65 polypeptide having a partial loss-of-function, a complete loss-of-function, a predicted partial loss-of-function, or a predicted complete loss-of-function. In any of the embodiments described herein, the predicted loss-of-function polypeptide of TRIM65 may be any of the TRIM65 polypeptides described herein.

[0045] In any of the embodiments described herein, the psoriasis is plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis, or any combination thereof. In any of the embodiments described herein, the psoriasis is guttate psoriasis. In any of the embodiments described herein, the psoriasis is plaque psoriasis. In any of the embodiments described herein, the psoriasis is inverse psoriasis. In any of the embodiments described herein, the psoriasis is pustular psoriasis. In any of the embodiments described herein, the psoriasis is erythrodermic psoriasis.

[0046] Symptoms of plaque psoriasis include raised, inflamed red lesions covered with scaly, silvery white plaques on the skin, typically occurring on elbows, knees, scalp, back, and lower back. Plaque psoriasis can also be found on nails, legs, hands, genitals, and breasts. Symptoms of guttate psoriasis include small, pink, individual spots that typically occur on the trunk, arms, and legs. Symptoms of inverse psoriasis include smooth, shiny, bright red lesions that typically occur in the armpits, groin, under the breasts, and in the skin folds around the genitals and buttocks. Symptoms of pustular psoriasis include non-infectious yellowish pustules surrounded by red skin that are limited to certain areas, such as the hands and feet, or cover the entire body. Symptoms of erythrodermic psoriasis include widespread areas of bright red skin and sheet-like scaling that typically cover most of the body surface.

[0047] The present disclosure provides a method of treating a subject with psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0048] The disclosure also provides a method of treating a subject with guttate psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0049] The disclosure also provides a method of treating a subject having plaque psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0050] The disclosure also provides a method of treating a subject with inverse psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0051] The disclosure also provides a method of treating a subject having pustular psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0052] The present disclosure also provides a method of treating a subject having erythrodermic psoriasis, the method comprising administering to the subject an IFIH1 inhibitor.

[0053] In some embodiments, the IFIH1 inhibitor comprises an inhibitory nucleic acid molecule. Examples of inhibitory nucleic acid molecules include, but are not limited to, antisense nucleic acid molecules, small interfering RNA (siRNA), and short hairpin RNA (shRNA). Such inhibitory nucleic acid molecules can be designed to target any region of the IFIH1 nucleic acid molecule. In some embodiments, the antisense RNA, siRNA, or shRNA hybridizes with a sequence in the genomic nucleic acid molecule or mRNA molecule of IFIH1 in the cells of the subject, and reduces the expression of the IFIH1 polypeptide. In some embodiments, the IFIH1 inhibitor comprises an antisense molecule, which hybridizes with the genomic nucleic acid molecule or mRNA molecule of IFIH1 in the cells of the subject, and reduces the expression of the IFIH1 polypeptide. In some embodiments, the IFIH1 inhibitor comprises an siRNA, which hybridizes with the genomic nucleic acid molecule or mRNA molecule of IFIH1 in the cells of the subject, and reduces the expression of the IFIH1 polypeptide. In some embodiments, the IFIH1 inhibitor comprises an shRNA, which hybridizes to an IFIH1 genomic nucleic acid molecule or an mRNA molecule and reduces expression of the IFIH1 polypeptide in cells of the subject.

[0054] The present disclosure also provides a method for treating a subject with psoriasis, comprising administering a TRIM65 inhibitor to the subject.In some embodiments, the psoriasis is guttate psoriasis, plaque psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.In some embodiments, the psoriasis is guttate psoriasis.In some embodiments, the psoriasis is plaque psoriasis.In some embodiments, the psoriasis is inverse psoriasis.In some embodiments, the psoriasis is pustular psoriasis.In some embodiments, the psoriasis is erythrodermic psoriasis.

[0055] In some embodiments, the TRIM65 inhibitor comprises an inhibitory nucleic acid molecule. Examples of inhibitory nucleic acid molecules include, but are not limited to, antisense nucleic acid molecules, small interfering RNA (siRNA), and short hairpin RNA (shRNA). Such inhibitory nucleic acid molecules can be designed to target any region of a TRIM65 nucleic acid molecule. In some embodiments, the antisense RNA, siRNA, or shRNA hybridizes with a sequence in a genomic nucleic acid molecule or mRNA molecule of TRIM65 in the cells of the subject, and reduces the expression of the TRIM65 polypeptide. In some embodiments, the TRIM65 inhibitor comprises an antisense molecule, which hybridizes with a genomic nucleic acid molecule or mRNA molecule of TRIM65 in the cells of the subject, and reduces the expression of the TRIM65 polypeptide. In some embodiments, the TRIM65 inhibitor comprises an siRNA, which hybridizes with a genomic nucleic acid molecule or mRNA molecule of TRIM65 in the cells of the subject, and reduces the expression of the TRIM65 polypeptide. In some embodiments, the TRIM65 inhibitor comprises an shRNA, which hybridizes to a TRIM65 genomic nucleic acid molecule or mRNA molecule and reduces expression of the TRIM65 polypeptide in cells of the subject.

[0056] The inhibitory nucleic acid molecule may comprise RNA, DNA, or both RNA and DNA. The inhibitory nucleic acid molecule may also be linked or fused to a heterologous nucleic acid sequence, for example, in a vector or to a heterologous label. For example, the inhibitory nucleic acid molecule may be in a vector that contains the inhibitory nucleic acid molecule and a heterologous nucleic acid sequence, or as an exogenous donor sequence that contains them. The inhibitory nucleic acid molecule may also be linked or fused to a heterologous label. The label may be directly detectable (e.g., a fluorophore, etc.) or indirectly detectable (e.g., a hapten, an enzyme, or a fluorophore quencher, etc.). Such labels may be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Such labels include, for example, radioisotope labels, pigments, dyes, chromogens, spin labels, and fluorescent labels. The label may be, for example, a chemiluminescent substance, a metal-containing substance, or an enzyme in the case of secondary enzymatic signal generation. The term "label" may also refer to a "tag" or hapten, which can selectively bind to a conjugated molecule, which is then used to generate a detectable signal when added with a substrate. For example, biotin can be used as a tag with an avidin or streptavidin conjugate of horseradish peroxidase (HRP) that binds to the tag, and can be tested to detect the presence of HRP using a calorimetric substrate (e.g., tetramethylbenzidine (TMB) or the like) or a fluorogenic substrate. Exemplary labels that can be used as purification-facilitating tags include, but are not limited to, myc, HA, FLAG or 3XFLAG, 6XHis or polyhistidine, glutathione-S-transferase (GST), maltose binding protein, epitope tags, or the Fc portion of an immunoglobulin. Numerous labels include, for example, particles, fluorophores, haptens, enzymes, and their calorimetric, fluorogenic, and chemiluminescent substrates, as well as other labels.

[0057] The inhibitory nucleic acid molecule may, for example, comprise nucleotides, or non-natural or modified nucleotides, such as nucleotide analogs or substitute nucleotides. Such nucleotides include nucleotides that contain modified bases, sugars, or phosphate groups, or that incorporate non-natural moieties into their structure. Examples of non-natural nucleotides include, but are not limited to, dideoxynucleotides, biotinylated nucleotides, aminated nucleotides, deaminated nucleotides, alkylated nucleotides, benzylated nucleotides, and fluorophore-labeled nucleotides.

[0058] The inhibitory nucleic acid molecule may also contain one or more nucleotide analogs or alternative nucleotides. A nucleotide analog is a nucleotide that contains a modification to either the base moiety, sugar moiety, or phosphate moiety. Modifications to the base moiety include, but are not limited to, natural and synthetic modifications of A, C, G, and T / U, as well as different purine or pyrimidine bases, such as pseudouridine, uracil-5-yl, hypoxanthine-9-yl (I), and 2-aminoadenine-9-yl. Modified bases include 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 5 ... These include, but are not limited to, auracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo (such as 5-bromo), 5-trifluoromethyl and other 5-substituted uracils and cytosines, 5-substituted uracils and cytosines, 7-methylguanine, 7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.

[0059] Nucleotide analogs may also include modifications to the sugar moiety, including, but not limited to, natural and synthetic modifications of ribose and deoxyribose. Sugar modifications include, but are not limited to, the following modifications at the 2' position: OH, F, O-, S-, or N-alkyl, O-, S-, or N-alkenyl, O-, S-, or N-alkynyl, or O-alkyl-O-alkyl, where the alkyl, alkenyl, and alkynyl are substituted or unsubstituted C 1-10 Alkyl or C 2-10 Alkenyl, and C 2-10 Exemplary 2' sugar modifications also include, but are not limited to, -O[(CH 2 ) n O] m CH 3 , -O(CH 2 ) n OCH 3 , -O(CH 2 ) n NH 2 , -O(CH 2 ) n CH 3 , -O(CH 2 ) n -ONH 2 , and -O(CH 2 ) n ON[(CH 2 ) n CH 3 )] 2 where n and m are independently 1 to about 10. Other modifications at the 2' position include, but are not limited to, C 1-10 Alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , S.O. 2 CH 3 , O.N.O. 2 , NO 2 , N 3 , N.H. 2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, RNA cleaving groups, reporter groups, intercalating agents, groups which improve the pharmacokinetic properties of an oligonucleotide, or groups which improve the pharmacodynamic properties of an oligonucleotide, and other substituents with similar properties. Similar modifications can also be made at other positions on the sugar, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides, and the 5' position of the 5' terminal nucleotide. Modified sugars include modifications at the bridging ring oxygen, e.g., CH 2 and S. Nucleotide sugar analogs can also have sugar mimetics, such as, for example, a cyclobutyl moiety in place of the pentofuranosyl sugar.

[0060] Nucleotide analogs may also be modified at the phosphate moiety. Modified phosphate moieties include, but are not limited to, those in which the bond between two nucleotides can be modified to include phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methylphosphonates and other alkylphosphonates (including 3'-alkylenephosphonates and chiralphosphonates), phosphinates, phosphoramidates (including 3'-aminophosphoramidates and aminoalkylphosphoramidates), thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates. These phosphate bonds or modified phosphate bonds between two nucleotides can be 3'-5' or 2'-5' bonds, and the bonds can include reverse polarity, for example, 3'-5' to 5'-3' or 2'-5' to 5'-2'. Also included are various salts, mixed salts, and free acid forms. Nucleotide alternatives also include peptide nucleic acids (PNAs).

[0061] In some embodiments, the antisense nucleic acid molecule is a gapmer in which the first 1-7 nucleotides at the 5' and 3' ends each have a 2'-methoxyethyl (2'-MOE) modification. In some embodiments, the first five nucleotides at the 5' and 3' ends each have a 2'-MOE modification. In some embodiments, the first 1-7 nucleotides at the 5' and 3' ends are RNA nucleotides. In some embodiments, the first five nucleotides at the 5' and 3' ends are RNA nucleotides. In some embodiments, each of the internucleotide backbone linkages is a phosphorothioate linkage.

[0062] In some embodiments, the siRNA molecule has terminal modification.In some embodiments, the 5'-end of the antisense strand is phosphorylated.In some embodiments, a 5'-phosphate analog that cannot be hydrolyzed, such as 5'-(E)-vinyl-phosphonate, is used.

[0063] In some embodiments, the siRNA molecule has a backbone modification. In some embodiments, modified phosphodiester groups linking consecutive ribose nucleosides have been shown to increase the stability and in vivo bioavailability of siRNA. The non-ester group (-OH, =O) of the phosphodiester bond can be replaced by sulfur, boron, or acetate to give phosphorothioate, boranophosphate, and phosphonoacetate bonds. In addition, the replacement of phosphodiester groups with phosphotriesters can facilitate cellular uptake of siRNA and retention in serum components by eliminating their negative charge. In some embodiments, the siRNA molecule has a sugar modification. In some embodiments, the sugar can be deprotonated (a reaction catalyzed by exonucleases and endonucleases), allowing the 2'-hydroxyl to act as a nucleophile and attack the adjacent phosphorus in the phosphodiester bond. Such alternatives include 2'-O-methyl, 2'-O-methoxyethyl, and 2'-fluoro modifications.

[0064] In some embodiments, the siRNA molecule has base modifications, in some embodiments, the bases can be replaced with modified bases, such as pseudouridine, 5'-methylcytidine, N6-methyladenosine, inosine, and N7-methylguanosine.

[0065] In some embodiments, the siRNA molecule is conjugated to lipid.Lipid can be conjugated to 5' or 3' end of siRNA to improve their in vivo bioavailability by associating them with serum lipoprotein.Representative lipids include, but are not limited to, cholesterol and vitamin E, and fatty acids such as palmitic acid and tocopherol.

[0066] In some embodiments, an exemplary siRNA has the formula: Sense: mN * mN * / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / * mN * / 32FN / Antisense: / 52FN / * / i2FN / * mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN / i2FN / mN * N * N where "N" is a base, "2F" is a 2'-F modification, "m" is a 2'-O-methyl modification, "I" is an internal base, and * " are phosphorothioate backbone linkages.

[0067] The present disclosure also provides a vector comprising any one or more of the inhibitory nucleic acid molecules. In some embodiments, the vector comprises any one or more of the inhibitory nucleic acid molecules and a heterologous nucleic acid. The vector can be a viral vector or a non-viral vector capable of transporting a nucleic acid molecule. In some embodiments, the vector is a plasmid or a cosmid (e.g., a circular double-stranded DNA to which additional DNA segments can be ligated). In some embodiments, the vector is a viral vector, and additional DNA segments can be ligated to the viral genome. Expression vectors include, but are not limited to, plasmids, cosmids, retroviruses, adenoviruses, adeno-associated viruses (AAV), plant viruses, such as cauliflower mosaic virus and tobacco mosaic virus, yeast artificial chromosomes (YACs), Epstein-Barr (EBV) derived episomes, and other expression vectors known in the art.

[0068] The present disclosure also provides a composition comprising any one or more of the inhibitory nucleic acid molecules. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the composition comprises a carrier and / or excipient. Examples of carriers include, but are not limited to, poly(lactic acid) (PLA) microspheres, poly(D,L-lactic-coglycolic acid) (PLGA) microspheres, liposomes, micelles, reverse micelles, lipid cochleates, and lipid microtubules. The carrier may comprise a buffered salt solution, such as PBS, HBSS, etc.

[0069] In some embodiments, the IFIH1 inhibitor or TRIM65 inhibitor comprises a nuclease agent that induces one or more nicks or double-strand breaks at the recognition sequence(s), or a DNA binding protein that binds to a recognition sequence in the genomic nucleic acid molecule of IFIH1 or TRIM65. The recognition sequence can be located in the coding region of the IFIH1 gene or TRIM65 gene, or in a regulatory region that affects the expression of the gene. The recognition sequence of the DNA binding protein or nuclease agent can be located in an intron, exon, promoter, enhancer, regulatory region, or any non-protein coding region. The recognition sequence can include or be close to the start codon of the IFIH1 gene or TRIM65 gene. For example, the recognition sequence can be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon. As another example, two or more nuclease agents can be used, each of which targets a nuclease recognition sequence that includes or is close to a start codon.As another example, two nuclease agents can be used, one of which targets a nuclease recognition sequence that includes or is close to a start codon, and the other of which targets a nuclease recognition sequence that includes or is close to a stop codon, and the cleavage by these nuclease agents can delete the coding region between the two nuclease recognition sequences.Any nuclease agent that induces a nick or double-strand break at a desired recognition sequence can be used in the methods and compositions disclosed herein.Any DNA binding protein that binds to a desired recognition sequence can be used in the methods and compositions disclosed herein.

[0070] Nuclease agents and DNA binding proteins suitable for use herein include, but are not limited to, zinc finger proteins or zinc finger nucleases (ZFN) pairs, transcription activator-like effector (TALE) proteins or transcription activator-like effector nucleases (TALEN), or clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas) systems. The length of the recognition sequence can vary, including, for example, recognition sequences of about 30-36 bp for zinc finger proteins or ZFN pairs, about 15-18 bp for each ZFN, about 36 bp for TALE proteins or TALEN, and about 20 bp for CRISPR / Cas guide RNA.

[0071] In some embodiments, a CRISPR / Cas system can be used to modify a genomic IFIH1 or TRIM65 nucleic acid molecule in a cell. The methods and compositions disclosed herein may use a CRISPR-Cas system by utilizing a CRISPR complex (comprising a guide RNA (gRNA) complexed with a Cas protein) for site-specific cleavage of an IFIH1 or TRIM65 nucleic acid molecule.

[0072] Cas proteins generally contain at least one RNA recognition or binding domain that can interact with gRNA. Cas proteins may also contain nuclease domains (such as DNase or RNase domains), DNA binding domains, helicase domains, protein-protein interaction domains, dimerization domains, and other domains. Suitable Cas proteins include, for example, wild-type Cas9 proteins and wild-type Cpf1 proteins (such as FnCpf1). Cas proteins may have full cleavage activity to create double-strand breaks in IFIH1 or TRIM65 genomic nucleic acid molecules, or may be nickases that create single-strand breaks in IFIH1 or TRIM65 genomic nucleic acid molecules. Additional examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12), Cas10, Cas10d, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (CasA), Cse2 (CasB), Cse3 (CasE), Cse4 (CasF), Cse5 (CasF), Cse6 (CasF), Cse7 (CasF), Cse8 (CasF), Cse9 (CasF), Cse1 (CasF), Cse2 (CasF), Cse3 (CasF), Cse4 (CasF), Cse5 (CasF), Cse6 (CasF), Cse7 (CasF), Cse8 (CasF), Cse9 (CasF), Cse1 ...1 (CasF), Cse1 (CasF), Cse1 (CasF), Cse1 (CasF), Cse1 (CasF), Cse1 (CasF), Cse Cas proteins include, but are not limited to, se4 (CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966, as well as homologs or modified forms thereof. Cas proteins can also be operably linked to heterologous polypeptides as fusion proteins. For example, Cas proteins can be fused to a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Cas proteins can be provided in any form. For example, the Cas protein may be provided in the form of a protein, e.g., a Cas protein complexed with a gRNA. Alternatively, the Cas protein may be provided in the form of a nucleic acid molecule, e.g., RNA or DNA, that encodes the Cas protein.

[0073] In some embodiments, targeted gene modification of a genomic nucleic acid molecule of IFIH1 or TRIM65 can be generated by contacting a cell with a Cas protein and one or more gRNAs that hybridize to one or more gRNA recognition sequences in a target genomic locus in a genomic nucleic acid molecule of IFIH1 or TRIM65. For example, the gRNA recognition sequence can be located within the region of SEQ ID NO: 1. The gRNA recognition sequence can also include or be close to the position corresponding to position 38,690 according to SEQ ID NO: 1. For example, the gRNA recognition sequence can be located about 1000, about 500, about 400, about 300, about 200, about 100, about 50, about 45, about 40, about 35, about 30, about 25, about 20, about 15, about 10, or about 5 nucleotides from the position corresponding to position 38,690 according to SEQ ID NO: 1. The gRNA recognition sequence may include or be close to the start codon of the IFIH1 or TRIM65 genomic nucleic acid molecule or the stop codon of the IFIH1 genomic nucleic acid molecule. For example, the gRNA recognition sequence may be located about 10, about 20, about 30, about 40, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon or the stop codon.

[0074] The gRNA recognition sequence in the target genomic locus in the IFIH1 or TRIM65 genomic nucleic acid molecule is located near a protospacer adjacent motif (PAM) sequence, which is a 2-6 base pair DNA sequence immediately following the DNA sequence targeted by Cas9 nuclease. A standard PAM is the sequence 5'-NGG-3', where "N" is any nucleobase followed by two guanine ("G") nucleobases. Although the gRNA can transport Cas9 anywhere in the genome for gene editing, editing cannot occur at sites other than the site where Cas9 recognizes the PAM. In addition, 5'-NGA-3' can be a highly efficient non-standard PAM for human cells. In general, the PAM is about 2-6 nucleotides downstream of the DNA sequence targeted by the gRNA. The PAM can be adjacent to the gRNA recognition sequence. In some embodiments, the gRNA recognition sequence can be adjacent to the PAM at the 3' end. In some embodiments, the gRNA recognition sequence may be flanked by the PAM at the 5' end. For example, the cleavage site of the Cas protein may be about 1 to about 10, about 2 to about 5 base pairs, or 3 base pairs upstream or downstream of the PAM sequence. In some embodiments (e.g., when Cas9 from S. pyogenes or a closely related Cas9 is used), the PAM sequence of the non-complementary strand may be 5'-NGG-3', where N is any DNA nucleotide, immediately 3' of the gRNA recognition sequence of the non-complementary strand of the target DNA. Thus, the PAM sequence of the complementary strand is 5'-CCN-3', where N is any DNA nucleotide, immediately 5' of the gRNA recognition sequence of the complementary strand of the target DNA.

[0075] gRNA is an RNA molecule that binds to Cas protein and targets the Cas protein to a specific position in the genomic nucleic acid molecule of IFIH1 or TRIM65. An exemplary gRNA is a gRNA that is effective for inducing Cas enzyme to bind to or cleave the genomic nucleic acid molecule of IFIH1 or TRIM65, and the gRNA comprises a DNA targeting segment that hybridizes to a gRNA recognition sequence in the genomic nucleic acid molecule of IFIH1 or TRIM65, which includes or is close to the position corresponding to position 38,690 according to SEQ ID NO: 1 (for IFIH1). For example, the gRNA can be selected to hybridize to a gRNA recognition sequence located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the position corresponding to position 38,690 according to SEQ ID NO: 1. Other exemplary gRNAs comprise a DNA targeting segment that hybridizes to a gRNA recognition sequence present in the genomic nucleic acid molecule of IFIH1 or TRIM65 that includes or is close to the start codon or the stop codon.For example, gRNA can be selected so that it hybridizes to a gRNA recognition sequence that is located about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the start codon or about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 100, about 200, about 300, about 400, about 500, or about 1,000 nucleotides from the stop codon. A suitable gRNA may comprise about 17 to about 25 nucleotides, about 17 to about 23 nucleotides, about 18 to about 22 nucleotides, or about 19 to about 21 nucleotides. In some embodiments, the gRNA may comprise 20 nucleotides.

[0076] Examples of suitable gRNA recognition sequences located within the human IFIH1 reference gene are shown in Table 1 as SEQ ID NOs: 24-34. [Table 1]

[0077] The Cas protein and the gRNA form a complex, and the Cas protein cuts the target IFIH1 or TRIM65 genomic nucleic acid molecule. The Cas protein can cut the nucleic acid molecule at a site inside or outside the nucleic acid sequence present in the target IFIH1 or TRIM65 genomic nucleic acid molecule to which the DNA targeting segment of the gRNA binds. For example, the formation of a CRISPR complex (comprising a gRNA hybridized to a gRNA recognition sequence and complexed with a Cas protein) can cut one or both strands at or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs from) the nucleic acid sequence present in the IFIH1 or TRIM65 genomic nucleic acid molecule to which the DNA targeting segment of the gRNA binds.

[0078] Such a method can result in, for example, a genomic nucleic acid molecule of IFIH1 or TRIM65 in which the region of the gene is disrupted, the start codon is disrupted, the stop codon is disrupted, or the coding sequence is disrupted or deleted.Optionally, the cell can be further contacted with one or more additional gRNAs that hybridize with additional gRNA recognition sequences in the target genomic locus of the IFIH1 or TRIM65 genomic nucleic acid molecule.By contacting the cell with one or more additional gRNAs (such as a second gRNA that hybridizes with a second gRNA recognition sequence), the cleavage by the Cas protein can create two or more double-strand breaks or two or more single-strand breaks.

[0079] In some embodiments, the method of treatment further comprises detecting the presence or absence of an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 in the subject's biological sample. As used throughout this disclosure, an "IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1" is any IFIH1 nucleic acid molecule (e.g., a genomic nucleic acid molecule, an mRNA molecule, or a cDNA molecule, etc.) that encodes an IFIH1 polypeptide having partial loss-of-function, complete loss-of-function, predicted partial loss-of-function, or predicted complete loss-of-function.

[0080] The present disclosure also provides a method of treating a subject with a therapeutic agent for treating or suppressing psoriasis, the subject having psoriasis.In some embodiments, the method includes obtaining or obtaining a biological sample from the subject, and determining whether the subject has an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 by performing or performing a sequence analysis in the biological sample to determine whether the subject has a genotype that includes an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1.In some embodiments, the method further includes administering or continuing the administration of a therapeutic agent for treating or suppressing psoriasis to a subject who is an IFIH1 reference at a standard dosage, and / or administering an IFIH1 inhibitor to the subject.In some embodiments, the method further includes administering or continuing the administration of a therapeutic agent for treating or suppressing psoriasis to a subject who is heterozygous for the IFIH1 missense variant nucleic acid molecule at the same or lower standard dosage, and / or administering an IFIH1 inhibitor to the subject. In some embodiments, the method further comprises administering or continuing to administer a therapeutic agent for treating or suppressing psoriasis to the subject homozygous for the IFIH1 missense variant nucleic acid molecule at a dose equal to or less than the standard dose.The presence of a genotype having an IFIH1 missense variant nucleic acid molecule that encodes the predicted loss-of-function polypeptide of IFIH1 indicates that the subject has a low risk of developing psoriasis.In some embodiments, the subject is IFIH1 reference.In some embodiments, the subject is heterozygous for an IFIH1 missense variant nucleic acid molecule that encodes the predicted loss-of-function polypeptide of IFIH1.

[0081] In the case of subjects who have been genotyped or identified as heterozygous for an IFIH1 reference or an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1, such subjects may be treated with an IFIH1 inhibitor as described herein.

[0082] Detecting the presence or absence of an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 in a biological sample from a subject and / or determining whether a subject has an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 may be performed by any of the methods described herein. In some embodiments, these methods may be performed in vitro. In some embodiments, these methods may be performed in situ. In some embodiments, these methods may be performed in vivo. In any of these embodiments, the nucleic acid molecule may be present in a cell obtained from the subject.

[0083] In some embodiments, the method of treatment further comprises detecting the presence or absence of predicted loss-of-function polypeptide of IFIH1 in the biological sample of the subject.In some embodiments, if the subject does not have predicted loss-of-function polypeptide of IFIH1, the subject is also administered a standard dose of a therapeutic agent for treating or suppressing psoriasis.In some embodiments, if the subject has predicted loss-of-function polypeptide of IFIH1, the subject is also administered a standard dose of a therapeutic agent for treating or suppressing psoriasis, the same or lower than the standard dose.

[0084] The present disclosure also provides a method of treating a subject with a therapeutic agent for treating or suppressing psoriasis, the subject having psoriasis. In some embodiments, the method includes obtaining or obtaining a biological sample from the subject, and performing or performing an assay in the biological sample to determine whether the subject has a predicted loss-of-function polypeptide of IFIH1, thereby determining whether the subject has a predicted loss-of-function polypeptide of IFIH1. If the subject does not have a predicted loss-of-function polypeptide of IFIH1, the therapeutic agent for treating or suppressing psoriasis is administered or continues to be administered to the subject at a standard dosage, and / or an IFIH1 inhibitor is administered to the subject. If the subject has a predicted loss-of-function polypeptide of IFIH1, the therapeutic agent for treating or suppressing psoriasis is administered or continues to be administered to the subject at a standard dosage or less, and / or an IFIH1 inhibitor is administered to the subject. The presence of a predicted loss-of-function polypeptide of IFIH1 indicates that the subject is at a low risk of developing psoriasis. In some embodiments, the subject has a predicted loss-of-function polypeptide of IFIH1. In some embodiments, the subject does not have a predicted loss-of-function polypeptide of IFIH1.

[0085] Detecting the presence or absence of a predicted loss-of-function polypeptide of IFIH1 in a biological sample from a subject and / or determining whether a subject has a predicted loss-of-function polypeptide of IFIH1 may be performed by any of the methods described herein. In some embodiments, the methods may be performed in vitro. In some embodiments, the methods may be performed in situ. In some embodiments, the methods may be performed in vivo. In any of these embodiments, the polypeptide may be present in a cell obtained from the subject.

[0086] In some embodiments, the IFIH1 inhibitor is a paramyxovirus V protein. In some embodiments, the IFIH1 inhibitor comprises a small molecule.

[0087] In any embodiment, in the case of a subject genotyped or identified as heterozygous for an IFIH1 reference or an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1, such subject may be treated with an inhibitor of type 1 interferon pathway. In some embodiments, the inhibitor of type 1 interferon pathway is an agonist of adenosine deaminase RNA-specific (ADAR). In some embodiments, the ADAR agonist is an ADAR protein. In some embodiments, the ADAR agonist is an ADAR agonist antibody. In some embodiments, the inhibitor of type 1 interferon pathway is an inhibitor of TRIM65. In some embodiments, the TRIM65 inhibitor comprises a small molecule. In some embodiments, the inhibitor of type 1 interferon pathway is an inhibitor of DEAD box polypeptide 58 ("DDX58") (i.e., RIG-1). DDX58 inhibitors include, but are not limited to, epigallocatechin gallate (EGCG) and BX795 (InvivoGen).

[0088] In some embodiments, the method of treatment further comprises detecting the presence or absence of a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 in the subject's biological sample. As used throughout this disclosure, a "TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65" is any TRIM65 nucleic acid molecule (such as a genomic nucleic acid molecule, an mRNA molecule, or a cDNA molecule) that encodes a TRIM65 polypeptide having partial loss of function, complete loss of function, predicted partial loss of function, or predicted complete loss of function.

[0089] The present disclosure also provides a method of treating a subject with a therapeutic agent for treating or suppressing psoriasis, the subject having psoriasis.In some embodiments, the method includes obtaining or obtaining a biological sample from the subject, and determining whether the subject has a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 by performing or performing a sequence analysis in the biological sample to determine whether the subject has a genotype that includes a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65.In some embodiments, the method further includes administering or continuing to administer a therapeutic agent for treating or suppressing psoriasis to the subject who is a TRIM65 reference at a standard dosage, and / or administering a TRIM65 inhibitor to the subject.In some embodiments, the method further includes administering or continuing to administer a therapeutic agent for treating or suppressing psoriasis to the subject who is heterozygous for the TRIM65 missense variant nucleic acid molecule at the same or lower standard dosage, and / or administering a TRIM65 inhibitor to the subject. In some embodiments, the method further comprises administering or continuing to administer a therapeutic agent for treating or suppressing psoriasis to the subject homozygous for the TRIM65 missense variant nucleic acid molecule at the same or lower dose as standard dose.The presence of a genotype with a TRIM65 missense variant nucleic acid molecule that encodes the predicted loss-of-function polypeptide of TRIM65 indicates that the subject has a low risk of developing psoriasis.In some embodiments, the subject is a TRIM65 reference.In some embodiments, the subject is heterozygous for a TRIM65 missense variant nucleic acid molecule that encodes the predicted loss-of-function polypeptide of TRIM65.

[0090] In the case of a subject who has been genotyped or identified as heterozygous for a TRIM65 reference or a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65, such subject may be treated with a TRIM65 inhibitor as described herein.

[0091] Detecting the presence or absence of a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 in a subject's biological sample and / or determining whether a subject has a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 may be performed by any of the methods described herein. In some embodiments, these methods may be performed in vitro. In some embodiments, these methods may be performed in situ. In some embodiments, these methods may be performed in vivo. In any of these embodiments, the nucleic acid molecule may be present in a cell obtained from the subject.

[0092] In some embodiments, the method of treatment further comprises detecting the presence or absence of a predicted loss-of-function polypeptide of TRIM65 in the subject's biological sample. In some embodiments, if the subject does not have a predicted loss-of-function polypeptide of TRIM65, the subject is also administered a standard dose of a therapeutic agent for treating or suppressing psoriasis. In some embodiments, if the subject has a predicted loss-of-function polypeptide of TRIM65, the subject is also administered a standard dose of a therapeutic agent for treating or suppressing psoriasis, the same or a lower dose.

[0093] The present disclosure also provides a method of treating a subject with a therapeutic agent for treating or suppressing psoriasis, the subject having psoriasis.In some embodiments, the method includes obtaining or obtaining a biological sample from the subject, and performing or performing an assay in the biological sample to determine whether the subject has a predicted loss-of-function polypeptide of TRIM65, thereby determining whether the subject has a predicted loss-of-function polypeptide of TRIM65.If the subject does not have a predicted loss-of-function polypeptide of TRIM65, the therapeutic agent for treating or suppressing psoriasis is administered or continues to be administered to the subject at a standard dosage, and / or a TRIM65 inhibitor is administered to the subject.If the subject has a predicted loss-of-function polypeptide of TRIM65, the therapeutic agent for treating or suppressing psoriasis is administered or continues to be administered to the subject at a standard dosage or less, and / or a TRIM65 inhibitor is administered to the subject.The presence of a predicted loss-of-function polypeptide of TRIM65 indicates that the subject is at a low risk of developing psoriasis. In some embodiments, the subject has a predicted loss-of-function polypeptide of TRIM65. In some embodiments, the subject does not have a predicted loss-of-function polypeptide of TRIM65.

[0094] Detecting the presence or absence of a predicted loss-of-function polypeptide of TRIM65 in a biological sample from a subject and / or determining whether a subject has a predicted loss-of-function polypeptide of TRIM65 may be performed by any of the methods described herein. In some embodiments, these methods may be performed in vitro. In some embodiments, these methods may be performed in situ. In some embodiments, these methods may be performed in vivo. In any of these embodiments, the polypeptide may be present in a cell obtained from the subject.

[0095] In some embodiments, the TRIM65 inhibitor is a peptide that blocks the interaction between TRIM65 and IFIH1.In some embodiments, the TRIM65 inhibitor comprises a small molecule.

[0096] In any embodiment, for subjects genotyped or identified as heterozygous for a TRIM65 reference or TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65, such subjects may be treated with a type 1 interferon pathway inhibitor and / or an IFIH1 inhibitor. In some embodiments, the type 1 interferon pathway inhibitor is an adenosine deaminase RNA-specific (ADAR) agonist. In some embodiments, the ADAR agonist is an ADAR protein. In some embodiments, the ADAR agonist is an ADAR agonist antibody. In some embodiments, the TRIM65 inhibitor comprises a small molecule. In some embodiments, the type 1 interferon pathway inhibitor is an inhibitor of DEAD box polypeptide 58 ("DDX58") (i.e., RIG-1). DDX58 inhibitors include, but are not limited to, epigallocatechin gallate (EGCG) and BX795 (InvivoGen).

[0097] Examples of therapeutic agents for treating or suppressing psoriasis include, but are not limited to, anthralin (dihydroxyanthralin), azarabine, colchicine, fluorouracil, methotrexate, methoxsalen (8-methoxypsoralen), resorcinol, retinoids (e.g., retinoic acid), corticosteroids (e.g., clobetasol propionate, triamcinolone acetonide), cyclosporine, iodochlorhydroxyquin, salicylic acid, vitamin D, dapsone, somatostatin, sulfur, tar, zinc oxide, hydroxycarbamide, fumarate (e.g., dimethyl fumarate), and ultraviolet light. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is anthralin (e.g., dihydroxyanthralin). In some embodiments, the therapeutic agent for treating or suppressing psoriasis is azarabine. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is colchicine. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is fluorouracil. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is methotrexate. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is methoxsalen (e.g., 8-methoxypsoralen). In some embodiments, the therapeutic agent for treating or suppressing psoriasis is resorcinol. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is a retinoid (e.g., retinoic acid). In some embodiments, the therapeutic agent for treating or suppressing psoriasis is a corticosteroid (e.g., clobetasol propionate, triamcinolone acetonide). In some embodiments, the therapeutic agent for treating or suppressing psoriasis is cyclosporine. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is iodochlorhydroxyquin. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is salicylic acid. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is vitamin D. In some embodiments, the therapeutic agent that treats or inhibits psoriasis is dapsone.In some embodiments, the therapeutic agent that treats or inhibits psoriasis is somatostatin.In some embodiments, the therapeutic agent for treating or suppressing psoriasis is sulfur. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is tar. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is zinc oxide. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is hydroxycarbamide. In some embodiments, the therapeutic agent for treating or suppressing psoriasis is a fumarate (e.g., dimethyl fumarate). In some embodiments, the therapeutic agent for treating or suppressing psoriasis is ultraviolet light.

[0098] In some embodiments, the dosage of the therapeutic agent for treating or suppressing psoriasis can be reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% (i.e., less than the standard dosage) for subjects who are heterozygous for IFIH1 or TRIM65 missense variant nucleic acid molecules that encode predicted loss-of-function polypeptides of IFIH1 or TRIM65 compared to subjects who are IFIH1 reference or TRIM65 reference (which can be administered the standard dosage). In some embodiments, the dosage of the therapeutic agent for treating or suppressing psoriasis can be reduced by about 10%, about 20%, about 30%, about 40%, or about 50%. In addition, the dose of a therapeutic agent for treating or suppressing psoriasis in a subject who is heterozygous for an IFIH1 or TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 or TRIM65 may be administered less frequently compared to a subject who is an IFIH1 reference or a TRIM65 reference.

[0099] The administration of the therapeutic agent for treating or suppressing psoriasis and / or the IFIH1 inhibitor / TRIM65 inhibitor / type 1 interferon pathway inhibitor can be repeated, for example, after 1 day, 2 days, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 1 month, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 2 months, or 3 months.The repeated administration can be performed with the same dose or with different doses.The administration can be repeated 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times.For example, according to a certain dosing regimen, the subject can be treated for a long period of time, for example, 6 months, 1 year, or more.

[0100] The administration of the therapeutic agent for treating or suppressing psoriasis and / or the IFIH1 inhibitor / TRIM65 inhibitor / type 1 interferon pathway inhibitor can be by any suitable route, including but not limited to parenteral, intravenous, oral, subcutaneous, intraarterial, intracranial, intrathecal, intraperitoneal, topical, intranasal, or intramuscular. The pharmaceutical composition for administration is desirably sterile and substantially isotonic and manufactured under GMP conditions. The pharmaceutical composition can be provided in unit dosage form (i.e., dosage for single administration). The pharmaceutical composition can be formulated using one or more physiologically and pharmacologic acceptable carriers, diluents, excipients, or adjuvants. The formulation depends on the route of administration selected. The term "pharmaceutical acceptable" means that the carrier, diluent, excipient, or adjuvant is compatible with the other ingredients of the formulation and is not substantially harmful to the recipient thereof.

[0101] As used herein, the terms "treat," "treating," and "treatment," as well as "prevent," "preventing," and "prevention," refer to eliciting a desired biological response, e.g., a therapeutic effect and a prophylactic effect, respectively. In some embodiments, the therapeutic effect comprises one or more of the following following administration of the agent or a composition comprising the agent: a reduction / reduction in psoriasis, a reduction / reduction in the severity of psoriasis (e.g., a reduction or inhibition of the onset or onset of psoriasis), a reduction / reduction in symptoms and psoriasis related effects, a delay in the onset of symptoms and psoriasis related effects, a reduction in the severity of symptoms of psoriasis related effects, a reduction in the severity of acute episodes, a reduction in the number of symptoms and psoriasis related effects, a reduction in the latency period of symptoms and psoriasis related effects, an improvement in symptoms and psoriasis related effects, a reduction in secondary symptoms, a reduction in secondary infections, prevention of recurrence of psoriasis, a reduction in the number or frequency of recurrent episodes, an increase in the latency period between symptomatic episodes, an increase in the time to sustained progression, a promotion of remission, an induction of remission, an increase in remission, an acceleration of recovery, or an increase in the effectiveness of or a decrease in resistance to alternative therapies, and / or an increase in the survival time of an affected host animal. A prophylactic effect can include complete or partial avoidance / inhibition, or delay (e.g., complete or partial avoidance / inhibition or delay, etc.) of the onset / progression of psoriasis following administration of a treatment protocol, and extending the survival time of the affected host animal. Treatment of psoriasis includes treatment of subjects already diagnosed with any form of psoriasis at any clinical stage or clinical manifestation, delaying the onset or progression or exacerbation or worsening of symptoms or signs of psoriasis, and / or preventing and / or reducing the severity of psoriasis.

[0102] The present disclosure also provides a method for diagnosing psoriasis in a subject, the method includes determining the total burden of a subject having a plurality of IFIH1 missense variant nucleic acid molecules that code for predicted loss-of-function polypeptides of IFIH1.If the subject has a lower total burden and has one or more symptoms of psoriasis, the subject is diagnosed as having psoriasis.If the subject has a higher total burden and does not have one or more symptoms of psoriasis, the subject is diagnosed as not having psoriasis.

[0103] The present disclosure also provides a method for identifying a subject at high risk of developing psoriasis. In some embodiments, the method comprises determining or having determined the presence or absence of an IFIH1 missense variant nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, and / or cDNA molecule) encoding a predicted loss-of-function polypeptide of IFIH1 in a biological sample obtained from the subject. If the subject lacks an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 (i.e., the subject is genotypically classified as IFIH1 reference), the subject is at high risk of developing psoriasis. If the subject has an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 (i.e., the subject is heterozygous for an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1), the subject is at low risk of developing psoriasis.

[0104] By having a single copy of the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1, the subject is more protected from developing psoriasis than if the subject does not have a copy of the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1. Without intending to be limited to any particular theory or mechanism of action, it is believed that a single copy of the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 (i.e., heterozygous for the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1) protects the subject from developing psoriasis, and similarly, it is believed that two copies of the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 (i.e., homozygous for the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1) may further protect the subject from developing psoriasis compared to a subject having a single copy. Thus, in some embodiments, a single copy of the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 may not be completely protective, but may instead partially or incompletely protect a subject from developing psoriasis.Without wishing to be bound by any particular theory, there may be additional factors or molecules involved in the development of psoriasis that are further present in the subject having a single copy of the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1, thereby resulting in less than complete protection from developing psoriasis.

[0105] Determining whether a subject has an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 in a biological sample of the subject and / or determining whether a subject has an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 may be performed by any of the methods described herein. In some embodiments, these methods may be performed in vitro. In some embodiments, these methods may be performed in situ. In some embodiments, these methods may be performed in vivo. In any of these embodiments, the nucleic acid molecule may be present in a cell obtained from the subject.

[0106] The present disclosure also provides a method for identifying a subject at high risk of developing psoriasis.In some embodiments, the method comprises determining or having determined the presence or absence of TRIM65 missense variant nucleic acid molecule (e.g., genomic nucleic acid molecule, mRNA molecule, and / or cDNA molecule) encoding predicted loss-of-function polypeptide of TRIM65 in a biological sample obtained from the subject.If the subject lacks the TRIM65 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of TRIM65 (i.e., the subject is genotypically classified as TRIM65 reference), the subject is at high risk of developing psoriasis.If the subject has the TRIM65 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of TRIM65 (i.e., the subject is heterozygous for the TRIM65 missense variant nucleic acid molecule encoding predicted loss-of-function polypeptide of TRIM65), the subject is at low risk of developing psoriasis.

[0107] By having a single copy of a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65, the subject is more protected from developing psoriasis than if the subject did not have a copy of a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65. Without intending to be limited to any particular theory or mechanism of action, it is believed that a single copy of a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 (i.e., heterozygous for a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65) protects the subject from developing psoriasis, and similarly, it is believed that two copies of a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 (i.e., homozygous for a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65) may further protect the subject from developing psoriasis compared to a subject having a single copy. Thus, in some embodiments, a single copy of a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 may not be completely protective, but may instead partially or incompletely protect a subject from developing psoriasis. Without wishing to be bound by any particular theory, there may be additional factors or molecules involved in the development of psoriasis that are further present in a subject having a single copy of a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65, thereby resulting in less than complete protection from developing psoriasis.

[0108] Determining whether a subject has a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 in a biological sample from the subject and / or determining whether a subject has a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 may be performed by any of the methods described herein. In some embodiments, these methods may be performed in vitro. In some embodiments, these methods may be performed in situ. In some embodiments, these methods may be performed in vivo. In any of these embodiments, the nucleic acid molecule may be present in a cell obtained from the subject.

[0109] In some embodiments, any of the methods described herein may further comprise determining the subject's total burden of having a predicted loss-of-function polypeptide of IFIH1 associated with a reduced risk of developing psoriasis, and / or an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function variant polypeptide of IFIH1. The total burden is the sum of all variants in the IFIH1 gene, which may be performed in an association analysis with psoriasis. In some embodiments, the subject is homozygous for one or more IFIH1 missense variant nucleic acid molecules encoding a predicted loss-of-function polypeptide of IFIH1 associated with a reduced risk of developing psoriasis. In some embodiments, the subject is heterozygous for one or more IFIH1 missense variant nucleic acid molecules encoding a predicted loss-of-function polypeptide of IFIH1 associated with a reduced risk of developing psoriasis. The results of the association analysis suggest that an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 is associated with a reduced risk of developing psoriasis. If the subject has a lower total load, the subject has a higher risk of developing psoriasis, and the subject is administered or continues to be administered with the therapeutic agent for treating or suppressing psoriasis at a standard dose.If the subject has a higher total load, the subject has a lower risk of developing psoriasis, and the subject is administered or continues to be administered with the therapeutic agent for treating or suppressing psoriasis at the same or lower dose than the standard dose.The higher the total load, the lower the risk of developing psoriasis.Table 2 lists the exemplary IFIH1 variant nucleic acid molecules that can be used for total load analysis. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4]

Table 2-5

Table 2-6

Table 2-7

Table 2-8

Table 2-9

Table 2-10

Table 2-11

Table 2-12

Table 2-13

Table 2-14

Table 2-15

Table 2-16

Table 2-17

Table 2-18

Table 2-19

Table 2-20

Table 2-21

Table 2-22

[0110] In some embodiments, the subject's total burden of having any one or more IFIH1 missense variant nucleic acid molecules encoding predicted loss-of-function polypeptides of IFIH1 represents a weighted sum of any multiple of the IFIH1 missense variant nucleic acid molecules encoding predicted loss-of-function polypeptides of IFIH1. In some embodiments, the total burden is calculated using at least about 2, at least about 3, at least about 4, at least about 5, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 100, at least about 120, at least about 150, at least about 200, at least about 250, at least about 300, at least about 400, at least about 500, at least about 1,000, at least about 10,000, at least about 100,000, or at least 1,000,000 or more genetic variants present in or surrounding the IFIH1 gene (up to 10 Mb), where the genetic burden is the number of alleles multiplied by the estimated association with psoriasis or a related outcome for each allele (e.g., a weighted polygenic burden score). This may include any genetic variants that are close to the IFIH1 gene (up to 10Mb around the gene) and show non-zero association with psoriasis-related traits in genetic association analysis, regardless of genome annotation.In some embodiments, if the subject has a total load higher than the desired threshold score, the subject has a low risk of developing psoriasis.In some embodiments, if the subject has a total load lower than the desired threshold score, the subject has a high risk of developing psoriasis.

[0111] In some embodiments, the total burden can be divided into quintiles, for example, top quintile, middle quintile, and bottom quintile, with the top quintile of total burden corresponding to the lowest risk group and the bottom quintile of total burden corresponding to the highest risk group. In some embodiments, the subjects with a larger total burden include the highest weighted total burden, including but not limited to the top 10%, top 20%, top 30%, top 40%, or top 50% of the total burden from the subject population. In some embodiments, the genetic variants include genetic variants that have an association with psoriasis in the top 10%, top 20%, top 30%, top 40%, or top 50% of the p-value range of the association. In some embodiments, each of the identified genetic variants is about 10 -2 Below, about 10 -3 Below, about 10 -4 Below, about 10 -5 Below, about 10 -6 Below, about 10 -7 Below, about 10 -8 Below, about 10 -9 Below, about 10 -10 Below, about 10 -11 Below, about 10 -12 Below, about 10 -13 Below, about 10 -14 Less than or equal to 10 -15 In some embodiments, the identified genetic variants have an association with psoriasis with a p-value of 5x10 -8In some embodiments, the identified genetic variants include genetic variants having an association with psoriasis in high risk subjects with an odds ratio (OR) of about 1.5 or more, about 1.75 or more, about 2.0 or more, or about 2.25 or more for the top 20% of the distribution, or about 1.5 or more, about 1.75 or more, about 2.0 or more, about 2.25 or more, about 2.5 or more, or about 2.75 or more for the remainder of the reference population. In some embodiments, the odds ratio (OR) can range from about 1.0 to about 1.5, about 1.5 to about 2.0, about 2.0 to about 2.5, about 2.5 to about 3.0, about 3.0 to about 3.5, about 3.5 to about 4.0, about 4.0 to about 4.5, about 4.5 to about 5.0, about 5.0 to about 5.5, about 5.5 to about 6.0, about 6.0 to about 6.5, about 6.5 to about 7.0, or more than 7.0. In some embodiments, high-risk subjects include subjects with a total burden in the bottom decile, quintile, or tertile in the reference population. The total burden threshold is determined based on the nature of the intended practical application and the risk difference that is considered meaningful for that practical application.

[0112] In some embodiments, if the subject is identified as being at high risk of developing psoriasis, the subject is further treated with a therapeutic agent for treating or suppressing psoriasis described herein, and / or an IFIH1 inhibitor, and / or a TRIM65 inhibitor, and / or an inhibitor of type 1 interferon pathway. For example, if the subject is IFIH1 reference and thus at high risk of developing psoriasis, the subject is administered an IFIH1 inhibitor. In some embodiments, such a subject is also administered a therapeutic agent for treating or suppressing psoriasis and / or an inhibitor of type 1 interferon pathway and / or an IFIH1 inhibitor. In some embodiments, if the subject is heterozygous for an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1, the subject is administered a therapeutic agent for treating or suppressing psoriasis at a standard dose or lower, and is also administered an IFIH1 inhibitor, and / or an inhibitor of type 1 interferon pathway and / or an IFIH1 inhibitor. In some embodiments, the subject is IFIH1 reference. In some embodiments, the subject is heterozygous for the IFIH1 missense variant nucleic acid molecule that encodes the predicted loss-of-function polypeptide of IFIH1.Furthermore, if the subject has a lower total burden of having the IFIH1 missense variant nucleic acid molecule that encodes the predicted loss-of-function polypeptide of IFIH1, and thus has a higher risk of developing psoriasis, the subject is administered a therapeutic agent that treats or suppresses psoriasis.In some embodiments, if the subject has a lower total burden of having the IFIH1 missense variant nucleic acid molecule that encodes the predicted loss-of-function polypeptide of IFIH1, the subject is administered a therapeutic agent that treats or suppresses psoriasis at a dose equal to or higher than the standard dose administered to the subject with a higher total burden of having the IFIH1 missense variant nucleic acid molecule that encodes the predicted loss-of-function polypeptide of IFIH1.

[0113] The present disclosure also provides a method for detecting the presence or absence of an IFIH1 or TRIM65 missense variant genomic nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 in a biological sample of a subject, and / or an IFIH1 or TRIM65 missense variant mRNA molecule encoding a predicted loss-of-function polypeptide of IFIH1 or TRIM65 in a biological sample of a subject, and / or an IFIH1 or TRIM65 missense variant cDNA molecule encoding a predicted loss-of-function polypeptide of IFIH1 or TRIM65 produced from an mRNA molecule in a biological sample of a subject. It is understood that gene sequences within a population and the mRNA molecules encoded by such genes may vary due to polymorphisms, e.g., single nucleotide polymorphisms. The sequences of the IFIH1 or TRIM65 missense variant genomic nucleic acid molecule, IFIH1 or TRIM65 missense variant mRNA molecule, and IFIH1 or TRIM65 missense variant cDNA molecule provided herein are merely exemplary sequences. Other sequences of the IFIH1 or TRIM65 missense variant genomic nucleic acid molecules, missense variant mRNA molecules, and missense variant cDNA molecules are also possible.

[0114] The biological sample may be derived from any cell, tissue, or biological fluid of the subject. The sample may include any clinically relevant tissue, such as bone marrow sample, tumor biopsy, fine needle aspirate, or a sample of bodily fluid, such as blood, gingival crevicular fluid, plasma, serum, lymph, ascites, cyst fluid, or urine. In some cases, the sample includes a buccal swab. The sample used in the methods disclosed herein may vary based on the assay format, the nature of the detection method, and the tissue, cell, or extract used as the sample. Depending on the assay used, the biological sample may be processed differently. For example, when detecting any IFIH1 missense variant nucleic acid molecule, a pre-processing designed to isolate or enrich the sample for genomic DNA may be used. A variety of techniques may be used for this purpose. When detecting any IFIH1 or TRIM65 missense variant mRNA level, a variety of techniques may be used to enrich the biological sample containing mRNA. A variety of methods may be used to detect the presence or level of mRNA, or the presence of a specific missense variant genomic DNA locus.

[0115] In some embodiments, detecting an IFIH1 or TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 or TRIM65 in a subject comprises assaying or genotyping a biological sample obtained from the subject to determine whether an IFIH1 or TRIM65 genomic nucleic acid molecule in the biological sample, and / or an IFIH1 or TRIM65 mRNA molecule in the biological sample, and / or an IFIH1 or TRIM65 cDNA molecule produced from an mRNA molecule in the biological sample contains one or more mutations that cause or are predicted to cause a loss of function (partial or complete).

[0116] In some embodiments, a method for detecting the presence or absence of an IFIH1 or TRIM65 missense variant nucleic acid molecule (e.g., a genomic nucleic acid molecule, an mRNA molecule, and / or a cDNA molecule produced from an mRNA molecule, etc.) encoding a predicted loss-of-function polypeptide of IFIH1 or TRIM65 in a subject comprises performing an assay on a biological sample obtained from the subject. The assay determines whether a nucleic acid molecule in the biological sample comprises a particular nucleotide sequence. In some embodiments, the IFIH1 nucleotide sequence comprises a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2 (relating to the genomic nucleic acid molecule).

[0117] In some embodiments, the biological sample comprises cells or cell lysates. Such methods may further comprise, for example, obtaining biological samples from the subject that comprise genomic nucleic acid molecules or mRNA molecules of IFIH1 or TRIM65, and, in the case of mRNA, optionally reverse transcribing the mRNA into cDNA. Such assays may comprise, for example, determining the identity of these positions of a particular IFIH1 or TRIM65 nucleic acid molecule. In some embodiments, the methods are in vitro methods.

[0118] In some embodiments, the determining step, detecting step, or sequence analysis comprises sequencing at least a portion of the nucleotide sequence of an IFIH1 or TRIM65 genomic nucleic acid molecule, an IFIH1 or TRIM65 mRNA molecule, or an IFIH1 or TRIM65 cDNA molecule in the biological sample, wherein the sequenced portion contains one or more mutations that cause or are predicted to cause loss of function (partial or complete).

[0119] In some embodiments, the determining step, detecting step, or sequence analysis comprises sequencing at least a portion of a nucleotide sequence of an IFIH1 genomic nucleic acid molecule in the biological sample, wherein the sequenced portion comprises a position corresponding to position 38,690 according to SEQ ID NO:2, or a complement thereof. If the sequenced portion of the IFIH1 nucleic acid molecule in the biological sample comprises a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2, then the IFIH1 nucleic acid molecule in the biological sample is an IFIH1 missense variant nucleic acid molecule that encodes a predicted loss-of-function polypeptide of IFIH1.

[0120] In some embodiments, the determining step, detecting step, or sequence analysis comprises: a) contacting the biological sample with a primer that hybridizes to a portion of the nucleotide sequence of an IFIH1 genomic nucleic acid molecule that is close to the position corresponding to position 38,690 according to SEQ ID NO:2; b) extending the primer through at least the position in the nucleotide sequence of an IFIH1 genomic nucleic acid molecule that corresponds to position 38,690 according to SEQ ID NO:2; and c) determining whether an extension product of the primer comprises a cytosine at the position corresponding to position 38,690 according to SEQ ID NO:2.

[0121] In some embodiments, the assay comprises sequencing the entire nucleic acid molecule. In some embodiments, only the genomic nucleic acid molecule of IFIH1 or TRIM65 is analyzed. In some embodiments, only the mRNA of IFIH1 or TRIM65 is analyzed. In some embodiments, only the cDNA of IFIH1 obtained from the mRNA of IFIH1 or TRIM65 is analyzed.

[0122] In some embodiments, the determining step, detecting step, or sequence analysis comprises: a) amplifying at least a portion of a nucleic acid molecule encoding a human IFIH1 polypeptide, wherein the amplified portion comprises a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2, or a complement thereof; b) labeling the amplified nucleic acid molecule with a detectable label; c) contacting the labeled nucleic acid molecule with a support comprising a mutation-specific probe, wherein the mutation-specific probe comprises a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid sequence of the amplified nucleic acid molecule comprising a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2, or a complement thereof; and d) detecting the detectable label.

[0123] In some embodiments, the nucleic acid molecule is mRNA and the determining step further comprises reverse transcribing the mRNA into cDNA prior to the amplifying step.

[0124] In some embodiments, the determining step, detecting step, or sequence analysis comprises: contacting a nucleic acid molecule in the biological sample with a mutation-specific probe comprising a detectable label, wherein the mutation-specific probe comprises a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence of an amplified nucleic acid molecule comprising a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2, or a complement thereof, and detecting the detectable label.

[0125] Mutation-specific polymerase chain reaction techniques can be used to detect mutations, such as SNPs, contained in nucleic acid sequences. Mutation-specific primers can be used because DNA polymerase will not extend if there is a mismatch with the template.

[0126] In some embodiments, the nucleic acid molecule in the sample is mRNA, and the mRNA is reverse transcribed into cDNA prior to the amplification step. In some embodiments, the nucleic acid molecule is present in a cell obtained from a human subject.

[0127] In some embodiments, the assay involves contacting the biological sample with a primer or probe, e.g., a mutation-specific primer or a mutation-specific probe, that specifically hybridizes under stringent conditions to a variant genomic, mRNA, or cDNA sequence of IFIH1 or TRIM65 and does not hybridize to a corresponding IFIH1 or TRIM65 reference sequence, and determining whether hybridization occurs.

[0128] In some embodiments, the assay comprises RNA sequencing (RNA-Seq). In some embodiments, the assay also comprises reverse transcribing mRNA into cDNA, for example, by reverse transcriptase polymerase chain reaction (RT-PCR).

[0129] In some embodiments, the method uses probes and primers of sufficient nucleotide length to bind to a target nucleotide sequence and specifically detect and / or distinguish polynucleotides containing IFIH1 or TRIM65 missense variant genomic nucleic acid molecules, missense variant mRNA molecules, or missense variant cDNA molecules. The hybridization or reaction conditions can be determined by the operator to achieve this result. The nucleotide length can be any length sufficient for use in the selected detection method, including any assay described or exemplified herein. Such probes and primers can specifically hybridize to the target nucleotide sequence under high stringency hybridization conditions. The probes and primers can have complete nucleotide sequence identity of consecutive nucleotides in the target nucleotide sequence, but probes that are different from the target nucleotide sequence and retain the ability to specifically detect and / or distinguish the target nucleotide sequence can be designed by conventional methods. The probes and primers can have about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% sequence identity or complementarity to the nucleotide sequence of the target nucleic acid molecule.

[0130] In some embodiments, to determine whether an IFIH1 nucleic acid molecule (genomic nucleic acid molecule, mRNA molecule, or cDNA molecule) in a biological sample, or its complement, contains a nucleotide sequence that includes a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2 (genomic nucleic acid molecule), the biological sample is subjected to an amplification method using a primer pair that includes a first primer derived from a 5' flanking sequence adjacent to the cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2 and a second primer derived from a 3' flanking sequence adjacent to the cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2, to produce an amplicon that indicates the presence of a SNP at a position that codes for a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2. In some embodiments, the amplicon can range in length from the length of the primer pair plus one nucleotide base pair to any length of an amplicon that can be produced by a DNA amplification protocol. This distance can range from one nucleotide base pair to the limit of the amplification reaction, or up to about 20,000 nucleotide base pairs. Optionally, the primer pair flanks a region comprising a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2 and at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more nucleotides on either side of the position comprising a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2.

[0131] Similar amplicons can be generated from the mRNA and / or cDNA sequences. PCR primer pairs can be obtained from known sequences using, for example, the PCR primer analysis tools in computer programs designed for this purpose, such as Vector NTI version 10 (Informax Inc., Bethesda Md.), PrimerSelect (DNASTAR Inc., Madison, Wis.), and Primer3 (Version 0.4.0.COPYRGT., 1991, Whitehead Institute for Biomedical Research, Cambridge, Mass.). In addition, sequences can be visually inspected and primers manually specified using known guidelines.

[0132] Illustrative examples of nucleic acid sequencing techniques include, but are not limited to, chain terminator (Sanger) sequencing and dye terminator sequencing. Other methods include nucleic acid hybridization methods other than sequencing, including using labeled primers or probes on purified DNA, amplified DNA, and fixed cell preparations (fluorescence in situ hybridization (FISH)). In some methods, the target nucleic acid molecule may be amplified prior to or simultaneously with detection. Illustrative examples of nucleic acid amplification techniques include, but are not limited to, polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), and nucleic acid sequence-based amplification (NASBA). Other methods include, but are not limited to, ligase chain reaction, strand displacement amplification, and thermophilic SDA (tSDA).

[0133] In hybridization techniques, stringent conditions can be used so that the probe or primer hybridizes specifically to its target. In some embodiments, under stringent conditions, the polynucleotide primer or probe hybridizes to its target sequence to a detectably higher degree than to other non-target sequences, for example, at least 2 times, at least 3 times, at least 4 times or more than background, including more than 10 times background. In some embodiments, under stringent conditions, the polynucleotide primer or probe hybridizes to its target nucleotide sequence to a detectably higher degree at least 2 times than to other nucleotide sequences. In some embodiments, under stringent conditions, the polynucleotide primer or probe hybridizes to its target nucleotide sequence to a detectably higher degree at least 3 times than to other nucleotide sequences. In some embodiments, under stringent conditions, the polynucleotide primer or probe hybridizes to its target nucleotide sequence to a detectably higher degree at least 4 times than to other nucleotide sequences. In some embodiments, under stringent conditions, a polynucleotide primer or probe will hybridize to its target nucleotide sequence to an extent that is detectably greater than 10-fold above background than to other nucleotide sequences. Stringent conditions are sequence-dependent and will be different in different circumstances.

[0134] Suitable stringency conditions that promote DNA hybridization, such as 6X sodium chloride / sodium citrate (SSC) at about 45° C., followed by a 2X SSC wash at 50° C., are known or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6. Typically, stringent conditions for hybridization and detection are those in which the salt concentration is less than about 1.5 M Na + ions, usually about 0.01 to 1.0 M Na+ The ionic concentration (or other salts) is pH 7.0-8.3, and the temperature is at least about 30°C for short probes (e.g., 10-50 nucleotides, etc.) and at least about 60°C for long probes (e.g., more than 50 nucleotides, etc.). Stringent conditions can also be achieved by the addition of destabilizing agents, such as formamide. Optionally, the wash buffer may contain about 0.1% to about 1% SDS. The duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours. The duration of washing is at least long enough to reach equilibrium.

[0135] The present disclosure also provides a method for detecting the presence of predicted loss-of-function polypeptide of IFIH1, comprising performing an assay in a sample obtained from a subject to determine whether the IFIH1 polypeptide of the subject comprises one or more mutations that cause the polypeptide to have loss of function (partial or complete) or predicted loss of function (partial or complete). The predicted loss-of-function polypeptide of IFIH1 can be any of the truncated variant polypeptides of IFIH1 described herein. In some embodiments, if the subject does not have a predicted loss-of-function polypeptide of IFIH1, the subject is at high risk of developing psoriasis. In some embodiments, if the subject has a predicted loss-of-function polypeptide of IFIH1, the subject is at low risk of developing psoriasis.

[0136] The present disclosure also provides a method for detecting the presence of a predicted loss-of-function polypeptide of TRIM65, comprising performing an assay in a sample obtained from a subject to determine whether the subject's TRIM65 polypeptide comprises one or more mutations that cause the polypeptide to have loss of function (partial or complete) or predicted loss of function (partial or complete).The predicted loss-of-function polypeptide of TRIM65 can be any of the variant polypeptides of TRIM65 described herein.In some embodiments, if the subject does not have a predicted loss-of-function polypeptide of TRIM65, the subject is at high risk of developing psoriasis.In some embodiments, if the subject has a predicted loss-of-function polypeptide of TRIM65, the subject is at low risk of developing psoriasis.

[0137] The disclosure also provides isolated nucleic acid molecules that hybridize to an IFIH1 or TRIM65 missense variant genomic nucleic acid molecule, an IFIH1 or TRIM65 missense variant mRNA molecule, and / or an IFIH1 or TRIM65 missense variant cDNA molecule (e.g., any of the genomic variant nucleic acid molecules, mRNA variant molecules, and cDNA variant molecules disclosed herein). In some embodiments, the isolated nucleic acid molecule hybridizes to a portion of an IFIH1 nucleic acid molecule that includes a position corresponding to position 38,690 according to SEQ ID NO:2.

[0138] In some embodiments, such isolated nucleic acid molecules comprise at least about 5, at least about 8, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, At least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 2000, at least about 3000, at least about 4000, or at least about 5000 nucleotides. In some embodiments, such isolated nucleic acid molecules comprise or consist of at least about 5, at least about 8, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, or at least about 25 nucleotides. In some embodiments, the isolated nucleic acid molecule comprises or consists of at least about 18 nucleotides. In some embodiments, the isolated nucleic acid molecule comprises or consists of at least about 15 nucleotides. In some embodiments, the isolated nucleic acid molecule comprises or consists of about 10 to about 35, about 10 to about 30, about 10 to about 25, about 12 to about 30, about 12 to about 28, about 12 to about 24, about 15 to about 30, about 15 to about 25, about 18 to about 30, about 18 to about 25, about 18 to about 24, or about 18 to about 22 nucleotides. In some embodiments, the isolated nucleic acid molecule comprises or consists of about 18 to about 30 nucleotides.In some embodiments, the isolated nucleic acid molecule comprises or consists of at least about 15 nucleotides to at least about 35 nucleotides.

[0139] In some embodiments, such isolated nucleic acid molecules hybridize under stringent conditions to an IFIH1 or TRIM65 missense variant nucleic acid molecule (e.g., a genomic nucleic acid molecule, an mRNA molecule, and / or a cDNA molecule). Such nucleic acid molecules can be used, for example, as probes, primers, mutation-specific probes, or mutation-specific primers described or exemplified herein, including, but not limited to, primers, probes, antisense RNA, shRNA, and siRNA, each of which is described in more detail elsewhere herein and can be used in any of the methods described herein.

[0140] In some embodiments, the isolated nucleic acid molecule hybridizes to at least about 15 contiguous nucleotides of a nucleic acid molecule that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an IFIH1 or TRIM65 missense variant genomic nucleic acid molecule, an IFIH1 or TRIM65 missense variant mRNA molecule, and / or an IFIH1 or TRIM65 missense variant cDNA molecule. In some embodiments, the isolated nucleic acid molecule consists of or comprises about 15 to about 100 nucleotides, or about 15 to about 35 nucleotides. In some embodiments, the isolated nucleic acid molecule consists of or comprises about 15 to about 100 nucleotides. In some embodiments, the isolated nucleic acid molecule consists of or comprises about 15 to about 35 nucleotides.

[0141] In some embodiments, the isolated mutation-specific probe or mutation-specific primer comprises at least about 15 nucleotides, and the mutation-specific probe or mutation-specific primer comprises a nucleotide sequence that is complementary to a portion of an IFIH1 missense variant nucleic acid molecule that encodes a predicted loss-of-function polypeptide of IFIH1, the portion comprising a position corresponding to position 38,690 according to SEQ ID NO:2, or a complement thereof.

[0142] In some embodiments, the mutation-specific probe and the mutation-specific primer comprise DNA. In some embodiments, the mutation-specific probe and the mutation-specific primer comprise RNA.

[0143] In some embodiments, the probes and primers described herein (including mutation-specific probes and mutation-specific primers) have a nucleotide sequence that specifically hybridizes to any of the nucleic acid molecules disclosed herein or their complements. In some embodiments, the probe or primer specifically hybridizes to any of the nucleic acid molecules disclosed herein under stringent conditions.

[0144] In some embodiments, the primers can be used in second generation or high throughput sequencing, including mutation specific primers. In some cases, the primers can be modified, including mutation specific primers. In particular, the primers can include various modifications used in various steps of, for example, Massive Parallel Signature Sequencing (MPSS), Polony sequencing, and 454 pyrosequencing. Modified primers can be used in several steps of the process, including biotinylated primers in the cloning step and fluorescently labeled primers used in the bead loading step and detection step. Polony sequencing is generally performed using paired-end tag libraries, where each molecule of DNA template is about 135 bp in length. Biotinylated primers are used in the bead loading step and emulsion PCR. Fluorescently labeled degenerate nonamer oligonucleotides are used in the detection step. The adapter can include a 5'-biotin tag for immobilizing the DNA library on streptavidin-coated beads.

[0145] The probes and primers described herein can be used to detect nucleotide variations in any of the IFIH1 or TRIM65 missense variant genomic nucleic acid molecules, IFIH1 or TRIM65 missense variant mRNA molecules, and / or IFIH1 or TRIM65 missense variant cDNA molecules disclosed herein. The primers described herein can be used to amplify IFIH1 or TRIM65 missense variant genomic nucleic acid molecules, IFIH1 or TRIM65 missense variant mRNA molecules, or IFIH1 or TRIM65 missense variant cDNA molecules, or fragments thereof.

[0146] The present disclosure also provides a pair of primers comprising any of the above primers.For example, if one of the 3' ends of the primer hybridizes to guanine (not cytosine) at the position corresponding to 38,690 according to SEQ ID NO:1 of a specific IFIH1 nucleic acid molecule, the presence of the amplified fragment indicates the presence of an IFIH1 reference genomic nucleic acid molecule.On the contrary, if one of the 3' ends of the primer hybridizes to cytosine (not guanine) at the position corresponding to 38,690 according to SEQ ID NO:2 of a specific IFIH1 nucleic acid molecule, the presence of the amplified fragment indicates the presence of an IFIH1 missense variant genomic nucleic acid molecule.In some embodiments, the nucleotide of the primer that is complementary to the cytosine at the position corresponding to 38,690 according to SEQ ID NO:2 can be the 3' end of the primer.

[0147] In the context of this disclosure, "specifically hybridizes" means that the probe or primer (e.g., a mutation-specific probe or a mutation-specific primer) does not hybridize to a nucleic acid sequence encoding an IFIH1 or TRIM65 reference genomic nucleic acid molecule, an IFIH1 or TRIM65 reference mRNA molecule, and / or an IFIH1 or TRIM65 reference cDNA molecule.

[0148] In some embodiments, the probe (e.g., a mutation-specific probe, etc.) comprises a label. In some embodiments, the label is a fluorescent label, a radioactive label, or biotin.

[0149] The present disclosure also provides a support comprising a substrate to which any one or more of the probes disclosed herein are attached. A solid support is a solid substrate or support to which molecules, such as any of the probes disclosed herein, can be associated. One form of solid support is an array. Another form of solid support is an array detector. An array detector is a solid support to which a plurality of different probes are attached in an array, grid, or other organized pattern. The form of solid substrate is a microtiter dish, such as a standard 96-well type. In some embodiments, a multi-well glass slide can be used, which usually contains one array per well.

[0150] The nucleotide sequence of the IFIH1 reference genome nucleic acid molecule is shown in SEQ ID NO: 1. This sequence corresponds to positions 162,267,074 to 162,318,684 of chromosome 2 according to the GRCh38 / hg38 human genome assembly (Gencode gene ENSG00000115267.8). With reference to SEQ ID NO: 1, position 38,690 is a guanine.

[0151] There is a variant genomic nucleic acid molecule of IFIH1 in which the guanine at position 38,690 is replaced by a cytosine, the nucleotide sequence of which is set forth in SEQ ID NO:2.

[0152] The nucleotide sequence of an IFIH1 reference mRNA molecule is set forth in SEQ ID NO: 3. The nucleotide sequence of another IFIH1 reference mRNA molecule is set forth in SEQ ID NO: 4. The nucleotide sequence of another IFIH1 reference mRNA molecule is set forth in SEQ ID NO: 5. The nucleotide sequence of another IFIH1 reference mRNA molecule is set forth in SEQ ID NO: 6. The nucleotide sequence of another IFIH1 reference mRNA molecule is set forth in SEQ ID NO: 7. The nucleotide sequence of another IFIH1 reference mRNA molecule is set forth in SEQ ID NO: 8. The nucleotide sequence of another IFIH1 reference mRNA molecule is set forth in SEQ ID NO: 9. The nucleotide sequence of another IFIH1 reference mRNA molecule is set forth in SEQ ID NO: 10.

[0153] The nucleotide sequence of an IFIH1 reference cDNA molecule is set forth in SEQ ID NO:11. The nucleotide sequence of another IFIH1 reference cDNA molecule is set forth in SEQ ID NO:12. The nucleotide sequence of another IFIH1 reference cDNA molecule is set forth in SEQ ID NO:13. The nucleotide sequence of another IFIH1 reference cDNA molecule is set forth in SEQ ID NO:14. The nucleotide sequence of another IFIH1 reference cDNA molecule is set forth in SEQ ID NO:15. The nucleotide sequence of another IFIH1 reference cDNA molecule is set forth in SEQ ID NO:16. The nucleotide sequence of another IFIH1 reference cDNA molecule is set forth in SEQ ID NO:17. The nucleotide sequence of another IFIH1 reference cDNA molecule is set forth in SEQ ID NO:18.

[0154] The genomic nucleic acid molecule, mRNA molecule, and cDNA molecule can be from any organism.For example, the genomic nucleic acid molecule, mRNA molecule, and cDNA molecule can be from human or another organism, such as non-human mammal, rodent, mouse, or rat, ortholog.It is understood that gene sequences in a population can differ due to polymorphism, such as single nucleotide polymorphism.The examples provided herein are only exemplary sequences.Other sequences are also possible.

[0155] Also provided herein is functional polynucleotide that can interact with the disclosed nucleic acid molecule.Examples of functional polynucleotide include, but are not limited to, antisense molecules, aptamers, ribozymes, triplex forming molecules, and external guide sequences.Said functional polynucleotide can act as effector, inhibitor, modulator, and stimulator of the specific activity of target molecule, or said functional polynucleotide can have de novo activity independent of any other molecule.

[0156] The isolated nucleic acid molecules disclosed herein may comprise RNA, DNA, or both RNA and DNA. The isolated nucleic acid molecules may also be linked or fused to heterologous nucleic acid sequences, for example in a vector, or to heterologous labels. For example, the isolated nucleic acid molecules disclosed herein may be present as exogenous donor sequences in or containing a vector that includes the isolated nucleic acid molecule and a heterologous nucleic acid sequence. The isolated nucleic acid molecules may also be linked or fused to heterologous labels. The labels may be directly detectable (e.g., fluorophores, etc.) or indirectly detectable (e.g., haptens, enzymes, or fluorophore quenchers, etc.). Such labels may be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Such labels include, for example, radioisotope labels, pigments, dyes, chromogens, spin labels, and fluorescent labels. The labels may be, for example, chemiluminescent, metal-containing, or enzymes where secondary enzymatic signal generation occurs. The term "label" may also refer to a "tag" or hapten, which can selectively bind to a conjugated molecule, which is then used to generate a detectable signal when added with a substrate. For example, biotin can be used as a tag with an avidin or streptavidin conjugate of horseradish peroxidase (HRP) that binds to the tag, and can be tested to detect the presence of HRP using a calorimetric substrate (e.g., tetramethylbenzidine (TMB) or the like) or a fluorogenic substrate. Exemplary labels that can be used as purification-facilitating tags include, but are not limited to, myc, HA, FLAG or 3XFLAG, 6XHis or polyhistidine, glutathione-S-transferase (GST), maltose binding protein, epitope tags, or the Fc portion of an immunoglobulin. Numerous labels include, for example, particles, fluorophores, haptens, enzymes, and their calorimetric, fluorogenic, and chemiluminescent substrates, as well as other labels.

[0157] Percent identity (or percent complementarity) between specific stretches of nucleotide sequences in nucleic acid molecules or amino acid sequences in polypeptides can be routinely determined using the BLAST program (basic local alignment search tool) and PowerBLAST program (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656), or the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.) using default settings that employ the Smith and Waterman algorithm (Adv. Appl. Math., 1981, 2, 482-489). When referring to percent sequence identity herein, a higher percentage of sequence identity is preferred over a lower one.

[0158] As used herein, the phrase "corresponding to" or grammatical variations thereof, when used in the context of a particular nucleotide or nucleotide sequence or position number, refers to the number of the specified reference sequence when the particular nucleotide or nucleotide sequence is compared to a reference sequence (e.g., SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:12, etc.). In other words, the residue (e.g., nucleotide or amino acid, etc.) number or residue (e.g., nucleotide or amino acid, etc.) position of a particular polymer is specified with respect to the reference sequence, not by the actual position number of that residue within the particular nucleotide or nucleotide sequence. For example, a particular nucleotide sequence can be aligned to a reference sequence by introducing gaps to optimize residue matching between the two sequences. In these cases, although gaps are present, the numbering of the residues in the particular nucleotide or nucleotide sequence is done with respect to the reference sequence to which it is aligned.

[0159] For example, a nucleic acid molecule comprising a nucleotide sequence encoding an IFIH1 polypeptide which comprises a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2 means that when the nucleotide sequence of said IFIH1 genomic nucleic acid molecule is aligned to the sequence of SEQ ID NO:2, said IFIH1 sequence has a guanine residue at a position corresponding to position 38,690 of SEQ ID NO:2. In other words, these terms refer to a nucleic acid molecule encoding an IFIH1 polypeptide which has a nucleotide sequence that includes a guanine residue that corresponds to the guanine residue at position 38,690 of SEQ ID NO:2.

[0160] As described herein, the position in the IFIH1 genomic nucleic acid molecule corresponding to position 38,690 according to SEQ ID NO:2 can be identified, for example, by performing sequence alignment between the nucleotide sequence of a particular IFIH1 nucleic acid molecule and the nucleotide sequence of SEQ ID NO:2. For example, there are various computer algorithms that can be used to perform sequence alignment to identify the position of the nucleotide corresponding to position 38,690 of SEQ ID NO:2. For example, sequence alignment can be performed by using the NCBI BLAST algorithm (Altschul et al., Nucleic Acids Res., 1997, 25, 3389-3402) or CLUSTALW software (Sievers and Higgins, Methods Mol. Biol., 2014, 1079, 105-116). However, sequences can also be aligned manually.

[0161] The amino acid sequence of the IFIH1 reference polypeptide is set forth in SEQ ID NO: 19 and is 1,025 amino acids in length. The amino acid sequence of another IFIH1 reference polypeptide is set forth in SEQ ID NO: 20 and is 986 amino acids in length. The amino acid sequence of another IFIH1 reference polypeptide is set forth in SEQ ID NO: 21 and is 468 amino acids in length. The amino acid sequence of another IFIH1 reference polypeptide is set forth in SEQ ID NO: 22 and is 772 amino acids in length. The amino acid sequence of another IFIH1 reference polypeptide is set forth in SEQ ID NO: 23 and is 221 amino acids in length.

[0162] The present disclosure also provides a therapeutic agent for treating or suppressing psoriasis for use in treating psoriasis in a subject having a genomic nucleic acid molecule having a nucleotide sequence encoding a predicted loss-of-function polypeptide of IFIH1.In some embodiments, the nucleic acid molecule comprises a nucleotide sequence comprising a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2, or its complement.The therapeutic agent for treating or suppressing psoriasis can be any of the therapeutic agents described herein.

[0163] The present disclosure also provides a therapeutic agent for treating or suppressing psoriasis for use in preparing a medicament for treating psoriasis in a subject having a genomic nucleic acid molecule having a nucleotide sequence encoding a predicted loss-of-function polypeptide of IFIH1.In some embodiments, the nucleic acid molecule comprises a nucleotide sequence comprising a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2, or its complement.The therapeutic agent for treating or suppressing psoriasis can be any of the therapeutic agents described herein.

[0164] The present disclosure also provides an IFIH1 inhibitor for use in treating psoriasis in a subject who is IFIH1 reference or is heterozygous for an IFIH1 missense variant nucleic acid molecule that encodes a predicted loss-of-function polypeptide of IFIH1.In some embodiments, the nucleic acid molecule comprises a nucleotide sequence that comprises a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2, or its complement.The IFIH1 inhibitor can be any of the IFIH1 inhibitors described herein.

[0165] The present disclosure also provides an IFIH1 inhibitor for use in preparing a medicament for treating psoriasis in a subject who is IFIH1 reference or is heterozygous for an IFIH1 missense variant nucleic acid molecule that encodes a predicted loss-of-function polypeptide of IFIH1.In some embodiments, the nucleic acid molecule comprises a nucleotide sequence that comprises a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:2, or its complement.The IFIH1 inhibitor can be any of the IFIH1 inhibitors described herein.

[0166] The present disclosure also provides a therapeutic agent for treating or suppressing psoriasis for use in treating psoriasis in a subject that is a reference to TRIM65 or a subject that is heterozygous for a TRIM65 missense variant nucleic acid molecule that encodes a predicted loss-of-function polypeptide of TRIM65.In some embodiments, the predicted loss-of-function polypeptide of TRIM65 is TRIM65 Gly382Arg.The therapeutic agent for treating or suppressing psoriasis can be any of the therapeutic agents described herein.

[0167] The present disclosure also provides a therapeutic agent for treating or suppressing psoriasis, for use in preparing a medicament for treating psoriasis in a subject that is a reference to TRIM65 or a subject that is heterozygous for a TRIM65 missense variant nucleic acid molecule that encodes a predicted loss-of-function polypeptide of TRIM65.In some embodiments, the predicted loss-of-function polypeptide of TRIM65 is TRIM65 Gly382Arg.The therapeutic agent for treating or suppressing psoriasis can be any of the therapeutic agents described herein.

[0168] The present disclosure also provides a TRIM65 inhibitor for use in treating psoriasis in a subject that is a TRIM65 reference or a subject that is heterozygous for a TRIM65 missense variant nucleic acid molecule that encodes a predicted loss-of-function polypeptide of TRIM65.In some embodiments, the predicted loss-of-function polypeptide of TRIM65 is TRIM65 Gly382Arg.The TRIM65 inhibitor can be any of the TRIM65 inhibitors described herein.

[0169] The present disclosure also provides a TRIM65 inhibitor for use in preparing a medicament for treating psoriasis in a subject that is a TRIM65 reference or a subject that is heterozygous for a TRIM65 missense variant nucleic acid molecule that encodes a predicted loss-of-function polypeptide of TRIM65.In some embodiments, the predicted loss-of-function polypeptide of TRIM65 is TRIM65 Gly382Arg.The TRIM65 inhibitor can be any of the TRIM65 inhibitors described herein.

[0170] All patent documents, websites, other publications, accession numbers, etc. cited above or below are hereby incorporated by reference to the same extent as if each item was specifically and individually indicated to be incorporated by reference in its entirety for all purposes. Where different versions of sequences are associated with accession numbers at different times, the version associated with the accession number at the effective filing date of this application is intended. Effective filing date means the earlier of the actual filing date or the filing date of the priority application that references the accession number, if applicable. Similarly, where different versions of publications, websites, etc. are published at different times, the version last published at the effective filing date of this application is intended, unless otherwise indicated. Any feature, step, element, embodiment, or aspect of the present disclosure may be used in combination with any other feature, step, element, embodiment, or aspect, unless otherwise indicated. Although the present disclosure has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be made within the scope of the appended claims.

[0171] To more fully describe the embodiments, the following examples are provided. These are intended to illustrate, not limit, the claimed embodiments. The following examples provide those skilled in the art with disclosures and descriptions of how the compounds, compositions, articles, devices and / or methods described herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the scope of any claims. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperatures, etc.), but some error and deviation can be accounted for. Unless otherwise indicated, parts are parts by weight, temperature is in °C or is ambient temperature, and pressure is at or near atmospheric pressure. EXAMPLES

[0172] Example 1: Haplotypes carrying common missense variants in IFIH1 are associated with a protective psoriasis phenotype A meta-analysis of several genetic cohorts (Table 3) was performed to identify novel genetic associations. [Table 3]

[0173] Significant common variant associations were found at known loci, including IFIH1, with a total of five common independent / novel signals found at known loci (data not shown). Additionally, independent and potentially novel common variant signals were identified in known GWAS regions / nearby regions (Table 4, gene=IFIH1, phenotype=psoriasis meta). Row 1: variant=2:162267541:C:T, rsID=rs1990760, and HGVS=missense Ala946Thr. Row 2: variant=2:162268127:T:C, rsID=rs35667974, and HGVS=missense Ile923Val. Row 3: variant=2:162279995:C:G, rsID=rs35337543, and HGVS=splice donor c.1641+1G>C). Line 4: variant = 2:162352383:T:G, rsID = rs17783344, and HGVS = missense Ser80Ala. [Table 4]

[0174] Specifically, this analysis identified a protective IFIH1 splice variant against psoriasis that was novel and independent of IFIH missense variants known to be associated with reduced odds of psoriasis.

[0175] This psoriasis meta-analysis also showed a significant association of IFIH1 gene burden with reduced odds of psoriasis, with additional IFIH1 pLoF and rare missense variants contributing to protection (Table 5, gene=IFIH1). [Table 5] Functional predictions = pLoF, <1% AAF (data row 1), pLoF, <0.1% AAF (data row 2), pLoF, <0.01% AAF (data row 3), pLoF and deleterious missense, <1% AAF (data row 4), pLoF and deleterious missense <0.1% AAF (data row 5), and pLoF and deleterious missense, <0.01% AAF (data row 6).

[0176] Additionally, significant gene burden associations were also shown for three genes in the type 1 interferon pathway: IFIH1, ADAR, and TRIM65 (Table 6, Genes = IFIH1 (data rows 1 and 2), ADAR (data rows 3 and 4), and TRIM65 (data rows 5 and 6)). [Table 6] Functional predictions = pLoF, <1% AAF (M1) (data row 1), pLoF and deleterious missense <1% AAF (M3) (data row 2), pLoF, <1% AAF (M1) (data row 3), pLoF and deleterious missense, <1% AAF (data row 4), pLoF, <1% AAF (M1) (data row 5), and pLoF and deleterious missense, <1% AAF (M3) (data row 6).

[0177] Furthermore, additional rare pLoF / deleterious missense variants in association with TRIM65 and reduced odds of psoriasis (Table 7). [Table 7] Functional prediction = pLoF, <1% AAF (M1) (data row 1), pLoF and deleterious missense, <1% AAF (M3) (data row 2), and missense p.Gly382Arg, 17:75891189:C:T (data row 3)

[0178] Finally, the data suggest that inhibition of TRIM65 may be protective in psoriasis (Table 8, variants = 7:75894282:G:A (data row 1) and 17:75891189:C:T (data row 2), rsID = rs55823223 (data row 1) and rs202175254 (data row), and HGVS = intronic c.415-1432C>T (data row 1) and missense p.Gly382Arg (data row 2), and Figure 1). [Table 8] Case RR|RA|AA = 7092|2603|247 (data row 1), and 18107|11|0 (data row 2). Control RR|RA|AA = 313749|102655|8980 (data row 1), and 568492|1074|1 (data row 2).

[0179] This meta-analysis also revealed a significant association for rare pLoF / deleterious heterozygous missense variants in ADAR1 and psoriasis (Table 9). [Table 9] Functional prediction = pLoF, <1% AAF (M1) (data row 1), and pLoF and deleterious missense, <1% AAF (M3) (data row 2)

[0180] Example 2: The TRIM65-G382R variant alters the cellular localization and expression levels of TRIM65 (Figure 2) Cell culture, plasmids and cell transfection: HEK293-HZ cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and antibiotics (50 units / mL penicillin and 50 μg / mL streptomycin, Thermo Fisher Scientific). pcDNA3.1 plasmids encoding N-terminal Flag-tagged wild-type TRIM65 or TRIM65-G382R, and N-terminal HA-tagged wild-type IFIH1 were synthesized by GenScript (USA). Cells at approximately 60–70% confluence were transiently transfected using FuGENE 6 (Promega) at a ratio of 1 μg DNA:5 ul FuGENE transfection reagent according to the manufacturer's protocol. After 48 hours, cells were washed with 1×DPBS (Thermo Fisher Scientific) and collected for downstream analysis.

[0181] Immunofluorescence assay: For immunofluorescence assays, cells were seeded in open 8-well μ-Slides (chamber slides) with glass bottom (Ibidi, Cat. No. 80827). The next day, cells were transfected with pcDNA3.1 plasmids encoding N-terminal Flag-tagged wild-type TRIM65 or TRIM65-G382R constructs with or without co-transfection of N-terminal HA-tagged WT IFIH1. 48 hours after transfection, cells were fixed with ice-cold 4% PFA for 10 min at RT and washed 3 times with ice-cold 1xDPBS (all subsequent washing steps were performed 3 times with ice-cold 1xDPBS, 5 min per wash). Cells were blocked with 10% normal donkey serum (NDS) containing 0.1% Triton X-100 (Jackson Immunoresearch Laboratories, #017-000-121). Cells were incubated overnight with anti-Flag (Sigma) and anti-HA (Cell Signaling) antibodies at 1:2000, washed, and then incubated for 1 hour with Alexa Fluor 594-conjugated anti-mouse secondary antibody at 1:1000 and Alexa Fluor 647-conjugated anti-rabbit secondary antibody at 1:1000 (Thermo Fisher Scientific). Wells were then washed and slides were mounted with ProLong® Gold antifade reagent with DAPI (Cell Signaling, #8961). Slides were imaged using a Zeiss confocal LSM880. Colocalization and Mander's overlap coefficients were calculated using ZEN Blue. Thresholds for each channel were estimated from single-labeled control wells.

[0182] Western Blotting: 10cm 248 hours after transfection in cell culture plates, HEK293HZ cells were pelleted and lysed in RIPA buffer supplemented with protease and kinase inhibitors. The following primary antibodies were used: anti-Flag M2 (mouse monoclonal, Sigma) and GAPDH 14C10 (rabbit mAb, Cell Signaling catalog number 2118). Immunoblots were detected and quantified using the appropriate LI-COR IRDye secondary antibodies (anti-rabbit (926-32211) and anti-mouse (926-32210)) using a LI-COR Odyssey infrared imaging system (LI-COR, Lincoln, NE).

[0183] Quantification of ISRE activity: HEK293-ISRE-luc cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) and antibiotics (50 units / mL penicillin and 50 μg / mL streptomycin, Thermo Fisher Scientific), 1xNEAA, and 1xL-glutamine. pcDNA3.1 plasmids encoding N-terminal eGFP-tagged wild-type TRIM65 or TRIM65-G382R were synthesized by GenScript (USA). Cells at approximately 60-70% confluence were transiently transfected using FuGENE 6 (Promega) at a ratio of 1 μg DNA:5 ul FuGENE transfection reagent according to the manufacturer's protocol. The next day, serum in the medium was reduced to 0.5% FBS, and 24 hours after transfection, cells were stimulated overnight with 0.05 μg HMW poly(i:c) (Invivogen) or 5000 U human IFN-α (R&D Systems). Luciferase activity was assessed using the Bright-Glo Luciferase Assay System (Promega) according to the manufacturer's protocol and read on a SpectraMax® i3x multimode microplate reader.

[0184] The results suggest that the TRIM65-G382R variant alters the cellular localization and expression level of TRIM65. TRIM65-G382R shows reduced colocalization with its binding partner IFIH1. This observation, together with the reduced interferon-stimulated response element (ISRE) activity in response to stimulation with IFN-α or poly(i:c) (an analogue of dsRNA known to activate IFIH1 in vitro) in cells transfected with the TRIM65-G382R construct, suggests that this variant may result in reduced interferon pathway activation, which may be protective against psoriasis.

[0185] In addition to those described herein, various modifications of the described subject matter will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application (including but not limited to journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, gene bank accession numbers, etc.) is incorporated herein by reference in its entirety.

Claims

1. 1. An in vitro method for identifying a subject's susceptibility to developing psoriasis, comprising: determining the presence or absence of an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of interferon-induced helicase C domain 1 (IFIH1) in a biological sample obtained from the subject; said subject's IFIH1 reference is indicative of said subject having an increased risk of developing psoriasis; The method, wherein the subject's heterozygosity or homozygosity for an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 is an indication that the subject has a low risk of developing psoriasis.

2. The method described in claim 1, wherein the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 is a genomic nucleic acid molecule having a nucleotide sequence including a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:

2.

3. The method described in claim 1 or 2, wherein the psoriasis is guttate psoriasis, plaque psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.

4. Use of a therapeutic agent that treats or inhibits psoriasis in the preparation of a medicament for the treatment of psoriasis in a subject identified as having an IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of interferon-induced helicase C domain 1 (IFIH1).

5. The use described in claim 4, wherein the IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1 is a genomic nucleic acid molecule having a nucleotide sequence including a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:

2.

6. The use described in claim 4, wherein the psoriasis is guttate psoriasis, plaque psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.

7. The use of any one of claims 4 to 6, wherein the therapeutic agent comprises anthralin, azarabine, colchicine, fluorouracil, methotrexate, methoxsalen, resorcinol, a retinoid, a corticosteroid, cyclosporine, iodochlorhydroxyquin, salicylic acid, vitamin D, dapsone, somatostatin, sulfur, tar, zinc oxide, hydroxycarbamide, fumarate, or ultraviolet light.

8. The anthralin comprising dihydroxyanthralin, the methoxsalen comprises 8-methoxypsoralen; the retinoid comprises retinoic acid; the corticosteroid comprises clobetasol propionate or triamcinolone acetonide; the fumarate comprises dimethyl fumarate; 8. The use according to claim 7.

9. Use of an interferon-inducible helicase C domain 1 (IFIH1) inhibitor in the preparation of a medicament for the treatment of psoriasis in a subject.

10. The use of claim 9, wherein the subject is heterozygous for an IFIH1 reference or IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1.

11. The use according to claim 10, wherein the IFIH1 missense variant nucleic acid molecule comprises a cytosine at a position corresponding to position 38,690 according to SEQ ID NO: 2, or a complement thereof.

12. The use according to claim 9 , wherein the IFIH1 inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to an IFIH1 nucleic acid molecule.

13. The use according to claim 12, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to IFIH1 mRNA.

14. The use of claim 9, wherein the IFIH1 inhibitor comprises a Cas protein and a guide RNA (gRNA) that hybridizes to a gRNA recognition sequence within an IFIH1 genomic nucleic acid molecule.

15. The use according to claim 14, wherein the Cas protein is Cas9 or Cpf1.

16. A method according to any one of claims 9 to 15, wherein the psoriasis is guttate psoriasis, plaque psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.

17. 1. An in vitro method for identifying a subject's susceptibility to developing psoriasis, comprising: determining the presence or absence of a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of Tripartite Motif Containing 65 (TRIM65) in a biological sample obtained from the subject; said subject's TRIM65 reference is indicative of said subject having an increased risk of developing psoriasis; The method, wherein the subject's heterozygosity or homozygosity for a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65 is an indication that the subject has a low risk of developing psoriasis.

18. 18. The method of claim 17, wherein the predicted loss-of-function polypeptide of TRIM65 is TRIM65 Gly382Arg.

19. The method described in claim 17 or 18, wherein the psoriasis is guttate psoriasis, plaque psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.

20. Use of a therapeutic agent that treats or inhibits psoriasis in the preparation of a medicament for the treatment of psoriasis in a subject identified as having a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of Tripartite Motif Containing 65 (TRIM65).

21. The use of claim 20, wherein the predicted loss-of-function polypeptide of TRIM65 is TRIM65 Gly382Arg.

22. The use described in claim 20, wherein the psoriasis is guttate psoriasis, plaque psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.

23. The use of any one of claims 20 to 22, wherein the therapeutic agent comprises anthralin, azarabine, colchicine, fluorouracil, methotrexate, methoxsalen, resorcinol, a retinoid, a corticosteroid, cyclosporine, iodochlorhydroxyquin, salicylic acid, vitamin D, dapsone, somatostatin, sulfur, tar, zinc oxide, hydroxycarbamide, fumarate, or ultraviolet light.

24. The anthralin comprising dihydroxyanthralin, the methoxsalen comprises 8-methoxypsoralen; the retinoid comprises retinoic acid; the corticosteroid comprises clobetasol propionate or triamcinolone acetonide; the fumarate comprises dimethyl fumarate; 24. The use according to claim 23.

25. Use of a Tripartite Motif Containing 65 (TRIM65) inhibitor for the preparation of a medicament for the treatment of psoriasis in a subject.

26. The use of claim 25, wherein the subject is heterozygous for a TRIM65 reference or a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65.

27. 27. The use of claim 26, wherein the predicted loss-of-function polypeptide of TRIM65 is TRIM65 Gly382Arg.

28. 26. The use according to claim 25, wherein the TRIM65 inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to a TRIM65 nucleic acid molecule.

29. The use according to claim 28, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to the mRNA of TRIM65.

30. The use described in any one of claims 25 to 29, wherein the psoriasis is guttate psoriasis, plaque psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.

31. A pharmaceutical composition for the treatment of psoriasis in a subject, comprising: A pharmaceutical composition comprising an interferon-inducible helicase C domain 1 (IFIH1) inhibitor as an active ingredient.

32. The pharmaceutical composition of claim 31, wherein the IFIH1 inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to an IFIH1 nucleic acid molecule.

33. The pharmaceutical composition of claim 32, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA).

34. The pharmaceutical composition described in claim 31, wherein the psoriasis is guttate psoriasis, plaque psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.

35. The use of any one of claims 31 to 34, wherein the subject is heterozygous or homozygous for an IFIH1 reference or IFIH1 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of IFIH1.

36. The pharmaceutical composition of claim 35, wherein the IFIH1 missense variant nucleic acid molecule encoding the predicted loss-of-function polypeptide of IFIH1 is a genomic nucleic acid molecule having a nucleotide sequence including a cytosine at a position corresponding to position 38,690 according to SEQ ID NO:

2.

37. A pharmaceutical composition for the treatment of psoriasis in a subject, comprising: A pharmaceutical composition comprising a Tripartite Motif Containing 65 (TRIM65) inhibitor as an active ingredient.

38. The pharmaceutical composition described in claim 37, wherein the TRIM65 inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to a TRIM65 nucleic acid molecule.

39. The pharmaceutical composition of claim 38, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA).

40. The pharmaceutical composition of claim 37, wherein the psoriasis is guttate psoriasis, plaque psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis.

41. A pharmaceutical composition described in any one of claims 37 to 40, wherein the subject is heterozygous or homozygous for a TRIM65 reference or a TRIM65 missense variant nucleic acid molecule encoding a predicted loss-of-function polypeptide of TRIM65.

42. The pharmaceutical composition of claim 41, wherein the predicted loss-of-function polypeptide of TRIM65 is TRIM65 Gly382Arg.

Images